FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of July 2020
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
1.
AZN: H1 2020 results
 
 
 
 
 
 
AstraZeneca PLC
30 July 2020 07:00 BST
H1 2020 results
A strong performance during the pandemic; a leader in the fight against COVID-19
 
During the COVID-19 global pandemic, AstraZeneca’s priority was and will continue to be the safe supply of medicines to millions of patients. In the first half, revenue, profit and cash-flow continued to grow. This performance was supported by successful launches of new medicines1 and more encouraging progress from the pipeline. The Company’s focus on growth through innovation is designed to support a continuation of these trends.
 
Pascal Soriot, Chief Executive Officer, commented:
“I want to thank my colleagues around the world for producing a strong performance in the first half of the year, delivering further revenue growth and another step forward in profitability and cash generation. I was particularly pleased with the robust growth in Emerging Markets and the success of our new medicines. We made further progress with our pipeline, highlighted by the overwhelming success of Tagrisso in the ADAURA trial and with Farxiga, which expanded its potential beyond diabetes. We are also pleased with our new collaboration with Daiichi Sankyo on DS-1062, which strengthens our growing Oncology portfolio.
 
Furthermore, our company has mounted a significant response to COVID-19, with capacity to deliver over two billion doses of AZD1222, the accelerated development of our monoclonal antibodies and new trials for the use of Calquence and Farxiga to treat patients affected by the virus.
 
Looking ahead, while we continue to anticipate variations in quarterly performance, the continuation of our strategy makes us confident about the future. We are retaining our full-year guidance that is underpinned by the focus on commercial execution and an exciting pipeline of new medicines.”
 
Financial performance
 
Table 1: Financial summary
 
H1 2020
Q2 2020
$m
% change
$m
% change
Actual
CER2
Actual
CER
Total Revenue
12,629
12
14
6,275
8
11
Product Sales
12,359
11
13
6,048
6
9
Collaboration Revenue
270
n/m3
n/m
227
n/m
n/m
 
 
 
 
 
 
 
Reported4 EPS5
$1.17
n/m
n/m
$0.58
n/m
n/m
Core6 EPS
$2.01
24
26
$0.96
32
31
 
There was only a modest inventory-related benefit to Total Revenue, reflecting the effects of the ongoing COVID-19 pandemic, in the first half of the year.
 
Total Revenue increased by 12% (14% at CER) to $12,629m in the half, with growth across all three therapy areas7 and in every region. Highlights of Total Revenue included:
 
- 
The performance of the new medicines, which improved by 42% (45% at CER) to $6,353m, including new-medicine growth in Emerging Markets of 71% (79% at CER) to $1,406m. These medicines represented 50% of global Total Revenue (H1 2019: 40%)
 
- 
Growth across all therapy areas: Oncology +28% (+31% at CER) to $5,324m, New CVRM8 +8% (+11% at CER) to $2,265m and Respiratory & Immunology +5% (+7% at CER) to $2,676m. In the second quarter, Respiratory & Immunology Total Revenue of $1,122m declined by 11% (8% at CER), reflecting the adverse impact of COVID-19 on sales of Pulmicort in China
 
- 
Growth in every region: an increase in Emerging Markets of 9% (15% at CER) to $4,329m, with China growth of 10% (14% at CER) to $2,659m. China increased by 7% in the second quarter (12% at CER) to $1,243m. Total Revenue in the US increased by 13% in the half to $4,177m and in Europe by 17% (20% at CER) to $2,447m
 
COVID-19
In addition to the array of efforts listed in the prior results announcement, the Company has mobilised research efforts to find new ways to help target the SARS-CoV-2 virus, reduce the cytokine storm9 and limit organ damage; for the latest AstraZeneca communications regarding COVID-19, please click here.
 
AstraZeneca has prioritised broad and equitable supply of a vaccine throughout the world at no profit during the pandemic, details of which can be found in the sustainability section of this document. In July 2020, results from the ongoing Phase I/II COV001 trial, led by the University of Oxford, were published in The Lancet showing that recombinant adenovirus vaccine AZD1222 (ChAdOx1 nCoV-19) was tolerated and generated robust immune responses against the SARS-CoV-2 virus in evaluated participants. Late-stage trials are currently underway in the UK, Brazil and South Africa and are due to start in the US. These trials will determine how well the vaccine will protect from the COVID-19 disease and measure safety and immune responses in different age ranges, at various doses.
 
Further details of the Company’s broad COVID-19 research and development programme and agreements to establish manufacturing capacity are shown later in this announcement.
 
Guidance
The Company provides guidance for FY 2020 at CER on:
 
- 
Total Revenue, comprising Product Sales and Collaboration Revenue
 
- 
Core EPS
 
Guidance partly reflects the changing nature and growing strategic impact of Collaboration Revenue which, over time, will primarily comprise potential income from various collaborations, including:
 
- 
A share of gross profits derived from sales of Enhertu in several markets, where those sales are recorded by Daiichi Sankyo Company, Limited (Daiichi Sankyo)
 
- 
A share of gross profits derived from sales of roxadustat in China recorded by FibroGen Inc. (FibroGen)10
 
- 
Milestone revenue from the MSD11 collaboration on Lynparza
 
- 
Smaller amounts of milestone and royalty revenue from other marketed and pipeline medicines
 
 

 Financial guidance for FY 2020 is unchanged. Total Revenue is expected to increase by a high single-digit to a low double-digit percentage and Core EPS is expected to increase by a mid- to high-teens percentage.
 
AstraZeneca recognises the heightened risks and uncertainties from the impact of COVID-19 referred to later in this announcement. Variations in performance between quarters can be expected to continue.
 

 
The Company is unable to provide guidance and indications on a Reported basis because AstraZeneca cannot reliably forecast material elements of the Reported result, including any fair-value adjustments arising on acquisition-related liabilities, intangible-asset impairment charges and legal-settlement provisions. Please refer to the cautionary-statements section regarding forward-looking statements at the end of this announcement.
 
Indications
The Company provides indications for FY 2020 at CER:
 
- 
The Company is focused on improving operating leverage
 
- 
A Core Tax Rate of 18-22%. Variations in the Core Tax Rate between quarters are anticipated to continue
 
- 
Capital Expenditure is expected to be broadly stable versus the prior year
 
Currency impact
If foreign-exchange rates for July to December 2020 were to remain at the average of rates seen in the half, it is anticipated that there would be a low single-digit adverse impact on Total Revenue and Core EPS. The Company’s foreign-exchange rate sensitivity analysis is contained within the operating and financial review.
 
Financial summary
- 
Total Revenue, comprising Product Sales and Collaboration Revenue, increased by 12% in the half (14% at CER) to $12,629m. Product Sales increased by 11% (13% at CER) to $12,359m, primarily driven by the performances of the new medicines within Emerging Markets and Oncology
 
- 
The Reported and Core Gross Profit Margins12 were stable at 81%; the Core Gross Profit Margin declined by one percentage point at CER, partly reflecting the impact of a one-off change in estimate relating to Group inventory valuation and the growth in profit share from the collaboration with MSD in respect of Lynparza. The Core Gross Profit Margin increased in the second quarter by two percentage points (one at CER) to 84%, reflecting the mix of Product Sales and manufacturing efficiencies
 
- 
Reported Total Operating Expense increased by 1% in the half (3% at CER) to $8,322m and represented 66% of Total Revenue (H1 2019: 73%). Core Total Operating Expense increased by 5% (7% at CER) to $7,256m and represented 57% of Total Revenue (H1 2019: 61%). The increases partly reflected investment in the pipeline, including the development of Enhertu and the ending in 2019 of the release of the upfront funding of Lynparza development as part of the aforementioned collaboration with MSD; Core R&D Expense increased by 8% in the half (9% at CER) to $2,712m. The increase in Core Total Operating Expense was also driven by additional SG&A investment in Oncology-medicine launches and AstraZeneca’s further expansion in China; Core SG&A Expense increased in the half by 2% (5% at CER) to $4,353m
 
- 
The Reported Operating Profit Margin increased in the half by six percentage points to 20%; the Core Operating Profit Margin increased by two percentage points to 29%
 
- 
Reported EPS of $1.17 in the half, representing an increase of 108% (106% at CER). Core EPS increased by 24% (26% at CER) to $2.01. This was despite an increase in the weighted-average number of shares to 1,312m (H1 2019: 1,289m)
 
- 
Net Cash Inflow from Operating Activities of $1,179m in the half represented a year-on-year increase of $688m, reflecting a $914m improvement in Reported Operating Profit to $2,504m
 
- 
An unchanged first interim dividend of $0.90 per share
 
Commercial summary
 
Oncology
Total Revenue increased by 28% in the half (31% at CER) to $5,324m.
 
Table 2: Select Oncology medicine performances
 
 
H1 2020
Q2 2020
$m
% change
$m
% change
Actual
CER
Actual
CER
Tagrisso: Product Sales
2,016
43
45
1,034
32
35
Imfinzi: Product Sales
954
51
52
492
46
48
Lynparza: Product Sales
816
57
60
419
48
52
Calquence: Product Sales
195
n/m
n/m
107
n/m
n/m
Enhertu: Collaboration Revenue
36
n/m
n/m
22
n/m
n/m
 
New CVRM
Total Revenue increased by 8% in the half (11% at CER) to $2,265m.
 
Table 3: Select New CVRM medicine performances
 
H1 2020
Q2 2020
$m
% change
$m
% change
Actual
CER
Actual
CER
Farxiga: Product Sales
848
17
21
443
17
23
Brilinta: Product Sales
845
15
17
437
12
16
Bydureon: Product Sales
216
(24)
(23)
116
(18)
(17)
Lokelma: Product Sales
28
n/m
n/m
17
n/m
n/m
Roxadustat: Collaboration Revenue
11
n/m
n/m
9
n/m
n/m
 
Respiratory & Immunology
Total Revenue increased by 5% in the half (7% at CER) to $2,676m.
 
Table 4: Select Respiratory & Immunology medicine performances
 
 
H1 2020
Q2 2020
$m
% change
$m
% change
Actual
CER
Actual
CER
Symbicort: Product Sales
1,442
23
26
653
12
15
Pulmicort: Product Sales
477
(33)
(32)
97
(71)
(69)
Fasenra: Product Sales
426
44
45
227
36
37
 
Sales of Pulmicort, of which the majority were in China, were adversely impacted in the half by the effects of COVID-19. Pulmicort sales in Emerging Markets declined by 36% (34% at CER) to $371m in the first half and by 78% (76% at CER) to $58m in the second quarter.
 
Emerging Markets
As the Company’s largest region, at 34% of Total Revenue, Emerging Markets increased by 9% in the half (15% at CER) to $4,329m, including:
 
- 
A China increase of 10% in the half (14% at CER) to $2,659m; the performance was adversely impacted by the aforementioned effects of COVID-19 on sales of Pulmicort. Q2 2020 Total Revenue increased by 7% (12% at CER) to $1,243m
 
- 
An ex-China increase of 8% in the half (15% at CER) to $1,671m. Q2 2020 Total Revenue increased by 4% (15% at CER) to $813m
 
Sustainability summary
Recent developments and progress against the Company’s sustainability priorities are reported below:
 
a) 
Access to healthcare
During the period, AstraZeneca advanced its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, AZD1222, following landmark agreements with the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the vaccine and parallel agreements with the UK Government, Europe’s Inclusive Vaccine Alliance (IVA), the Coalition for Epidemic Preparedness Innovations (CEPI) and Gavi, The Vaccine Alliance (GAVI). In addition, the Company reached a licensing agreement with Serum Institute of India (SII) to supply low-and-middle-income countries and agreements with R-Pharm in Russia and SK Biopharmaceuticals Co., Ltd in the Republic of Korea to manufacture and export for other global markets. Across the world, these parallel agreements helped to provide total manufacturing capacity of over two billion doses of the vaccine to support broad and equitable access, at no profit to AstraZeneca during the pandemic.
 
b) 
Environmental protection
Pascal Soriot was one of 17613 business leaders from member companies of the Science-Based Targets initiative that signed a recent statement urging governments around the world to align their COVID-19 economic aid and recovery efforts with the latest climate science, which was announced by the UN Global Compact (UNGC) in May 2020.
 
c) 
Ethics and transparency
Highlighting the Company’s continued commitment to inclusion and diversity, AstraZeneca was recognised by DiversityInc as one of the 2020 Top 50 Companies for Diversity; the Company was also named by DiversityInc as a Top Company for lesbian, gay, bisexual, and transgender (LGBT) employees.
 
A more extensive sustainability update is provided later in this announcement.
 
Notes
The following notes refer to pages one to five.
 
1.
Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Koselugo, Farxiga, Brilinta, Lokelma, roxadustat, Fasenra, Bevespi and Breztri. The new medicines are pillars in the three therapy areas of Oncology, Cardiovascular (CV), Renal & Metabolism (CVRM), and Respiratory & Immunology and are important platforms for future growth. The Total Revenue of Enhertu and roxadustat in the half entirely reflected Ongoing Collaboration Revenue.
2.
Constant exchange rates. These are financial measures that are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.
3.
Not meaningful.
4.
Reported financial measures are the financial results presented in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board and adopted by the EU. The UK is in the process of establishing its post-Brexit IFRS-adoption authority, which is expected to be operational later in 2020, but for the current time, will follow the EU approval process.
5.
Earnings per share.
6.
Core financial measures. These are non-GAAP financial measures because, unlike Reported performance, they cannot be derived directly from the information in the Group’s Interim Financial Statements. See the operating and financial review for a definition of Core financial measures and a reconciliation of Core to Reported financial measures.
7.
Defined here as Oncology, New CVRM and Respiratory & Immunology.
8.
New CVRM comprises Brilinta, Renal and Diabetes medicines.
9.
A severe immune reaction in which the body releases too many cytokines into the blood too quickly. Cytokines are cell signalling proteins that aid communication in innate and adaptive immune responses, stimulating cell movement towards sites of inflammation and infection.
10.
FibroGen and AstraZeneca are collaborating on the development and commercialisation of roxadustat in the US, China, and other global markets. FibroGen and Astellas Pharma Inc. (Astellas) are collaborating on the development and commercialisation of roxadustat in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East and South Africa.
11.
Merck & Co., Inc., Kenilworth, NJ, US, known as MSD outside the US and Canada.
12.
Gross Profit is defined as Total Revenue minus Cost of Sales. The calculation of Reported and Core Gross Profit Margin excludes the impact of Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales.
13.
As of 1 July 2020.
 
Table 5: Pipeline highlights
 
The following table highlights significant developments in the late-stage pipeline since the prior results announcement:
 
Regulatory approvals
-   Lynparza - ovarian cancer (1st line, HRD+1) (PAOLA-1) (US)
-   Lynparza - pancreatic cancer (1st line, BRCAm2) (EU)
-   Lynparza - prostate cancer (2nd line, HRRm3) (US)
 
-   Farxiga - HF4 CVOT5 (US)
-  Brilinta - CAD6/T2D7 CVOT (US)
 
-   Bevespi - COPD8 (CN)
-   Breztri - COPD (US)
Regulatory submission acceptances and/or submissions
-   Enhertu - breast cancer (3rd line, HER2+9) (EU)
-   Enhertu - gastric cancer (3rd line, HER2+) (JP)
 
-   Brilinta/Brilique - stroke (THALES) (US, EU)
Major Phase III data readouts or other significant developments
-   Imfinzi - ES10-SCLC11: positive opinion (EU)
-   Enhertu - breast cancer (3rd line, HER2+): accelerated assessment (EU)
-   Enhertu - gastric cancer (HER2+): Orphan Drug Designation, Breakthrough Therapy Designation (US)
-   Enhertu - NSCLC12 (2nd line, HER2m13): Breakthrough Therapy Designation (US)
-  Calquence - CLL14: positive opinion (EU)
-  selumetinib - NF115: orphan drug designation (JP)
 
-   Farxiga - CKD16: primary, all secondary endpoints met
-   Brilinta - stroke (THALES): Priority Review (US)
 
Table 6: Pipeline - anticipated major news flow
Innovation is critical to addressing unmet patient needs and is at the heart of the Company’s growth strategy. The focus on research and development is designed to yield strong and sustainable results from the pipeline.
 
Timing
News flow
H2 2020
-  Tagrisso - adjuvant NSCLC (EGFRm17): regulatory submission
-   Imfinzi - unresectable18, Stage III NSCLC (PACIFIC-2): data readout
-   Imfinzi - ES-SCLC: regulatory decision (EU, JP)
-   Imfinzi +/- treme19 - liver cancer (1st line): data readout, regulatory submission
-   Lynparza - ovarian cancer (1st line) (PAOLA-1): regulatory decision (EU, JP)
-   Lynparza - ovarian cancer (3rd line, BRCAm): regulatory submission
-   Lynparza - breast cancer (BRCAm): regulatory decision (CN)
-   Lynparza - prostate cancer (2nd line): regulatory decision (EU)
-   Enhertu - breast cancer (3rd line, HER2+): regulatory decision (EU)
-   Enhertu - gastric cancer (3rd line, HER2+): regulatory decision (JP)
-   Calquence - CLL: regulatory decision (EU)
 
-  Forxiga - T2D CVOT: regulatory decision (CN)
-  Forxiga - HF CVOT: regulatory decision (EU, JP)
-  Farxiga - CKD: regulatory submission
-   Brilinta - stroke (THALES): regulatory decision (US)
-   Brilinta - stroke (THALES): regulatory submission (CN)
-   roxadustat - anaemia in CKD: regulatory decision (US)
 
-  Symbicort - mild asthma: regulatory decision (CN)
-  Symbicort - mild asthma: regulatory submission (EU)
-  Fasenra - nasal polyposis20: data readout
-  PT010 - COPD: regulatory decision (EU)
-  tezepelumab - severe asthma: data readout
-  anifrolumab - lupus (SLE21): regulatory submission
-  AZD1222 - SARS-CoV-2: data readout, regulatory submission
H1 2021
-   Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2): regulatory submission
-   Imfinzi - NSCLC (1st line) (PEARL): data readout
-   Imfinzi +/- treme - head & neck cancer (1st line): data readout, regulatory submission
-   Lynparza - pancreatic cancer (1st line, BRCAm): regulatory decision (JP)
-  Lynparza - prostate cancer (2nd line): regulatory decision (JP)
-   Lynparza - adjuvant breast cancer: data readout
-   Calquence - CLL: regulatory decision (JP)
-   Koselugo - NF1 regulatory decision (EU)
 
-   Forxiga - HF CVOT: regulatory decision (CN)
-  Brilique/Brilinta - CAD/T2D CVOT: regulatory decision (EU, JP, CN)
-   Brilique - stroke (THALES): regulatory decision (EU)
 
-   Fasenra - nasal polyposis: regulatory submission
-   tezepelumab - severe asthma: regulatory submission
H2 2021
-   Imfinzi - NSCLC (1st line) (PEARL): regulatory submission
-   Imfinzi - adjuvant bladder cancer: data readout
-   Imfinzi - liver cancer (locoregional): data readout, regulatory submission
-   Imfinzi - biliary tract cancer: data readout
-  Imfinzi +/- treme - NSCLC (1st line) (POSEIDON): data readout (OS), regulatory submission
-   Lynparza - adjuvant breast cancer: regulatory submission
-   Lynparza - prostate cancer (1st line, castration-resistant): data readout, regulatory submission
-   Enhertu - breast cancer (3rd line, HER2+) (Phase III): data readout
-   Enhertu - breast cancer (2nd line, HER2+): data readout, regulatory submission
-   Enhertu - breast cancer (HER2 low22): data readout
-   Calquence - CLL (2nd line) (ELEVATE R/R): data readout, regulatory submission
 
-  Farxiga - HF (HFpEF23): data readout, regulatory submission
 
-  PT027 - asthma: data readout, regulatory submission
 
Conference call
A conference call and webcast for investors and analysts will begin at 11:45am UK time today. Details can be accessed via astrazeneca.com.
 
Report calendar
The Company intends to publish its year-to-date and third-quarter results on Thursday, 5 November 2020.
 
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Operating and financial review
 
All narrative on growth and results in this section is based on actual exchange rates, and financial figures are in US$ millions ($m), unless stated otherwise. The performance shown in this announcement covers the six-month period to 30 June 2020 (the half or H1 2020) and the three-month period to 30 June 2020 (the second quarter or Q2 2020) compared to the six-month period to 30 June 2019 (H1 2019) and three-month period to 30 June 2019 (Q2 2019) respectively, unless stated otherwise.
 
Core financial measures, EBITDA, Net Debt, Initial Collaboration Revenue and Ongoing Collaboration Revenue are non-GAAP financial measures because they cannot be derived directly from the Group’s Interim Financial Statements. Management believes that these non-GAAP financial measures, when provided in combination with Reported results, will provide investors and analysts with helpful supplementary information to understand better the financial performance and position of the Group on a comparable basis from period to period. These non-GAAP financial measures are not a substitute for, or superior to, financial measures prepared in accordance with GAAP. Core financial measures are adjusted to exclude certain significant items, such as:
 
- 
Amortisation and impairment of intangible assets, including impairment reversals but excluding any charges relating to IT assets
 
- 
Charges and provisions related to restructuring programmes, which includes charges that relate to the impact of restructuring programmes on capitalised IT assets
 
- 
Other specified items, principally comprising acquisition-related costs, which include fair-value adjustments and the imputed finance charge relating to contingent consideration on business combinations and legal settlements
 
Details on the nature of Core financial measures are provided on page 80 of the Annual Report and Form 20-F Information 2019. Reference should be made to the Reconciliation of Reported to Core financial measures table included in the financial performance section of this announcement.
 
EBITDA is defined as Reported Profit Before Tax after adding back Net Finance Expense, results from Joint Ventures and Associates and charges for Depreciation, Amortisation and Impairment. Reference should be made to the Reconciliation of Reported Profit Before Tax to EBITDA included in the financial performance section of this announcement.
 
Net Debt is defined as Interest-bearing loans and borrowings and Lease liabilities, net of Cash and cash equivalents, Other investments, and net Derivative financial instruments. Reference should be made to Note 3 ‘Net Debt’ included in the Notes to the Interim Financial Statements in this announcement.
 
Ongoing Collaboration Revenue is defined as Collaboration Revenue excluding Initial Collaboration Revenue (which is defined as Collaboration Revenue that is recognised at the date of completion of an agreement or transaction, in respect of upfront consideration). Ongoing Collaboration Revenue comprises, among other items, royalties, milestone revenue and profit-sharing income. Reference should be made to the Collaboration Revenue table in this operating and financial review.
 
The Company strongly encourages investors and analysts not to rely on any single financial measure, but to review AstraZeneca’s financial statements, including the Notes thereto and other available Company reports, carefully and in their entirety.
 
Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
 
Table 7: Total Revenue by therapy area
Specialty-care medicines comprise all Oncology medicines, Brilinta, Lokelma, roxadustat and Fasenra. At 53% of Total Revenue (H1 2019: 46%), specialty-care medicines increased by 28% in the half (30% at CER) to $6,634m.
 
 
H1 2020
Q2 2020
$m
% of total
% change
$m
 % of total
% change
Actual
CER
Actual
CER
Oncology
5,324
42
28
31
2,806
45
25
28
BioPharmaceuticals
4,941
39
7
9
2,285
36
(1)
2
New CVRM
2,265
18
8
11
1,163
19
10
13
Respiratory & Immunology
2,676
21
5
7
1,122
18
(11)
(8)
Other medicines
2,364
19
(7)
(4)
1,184
19
(6)
(2)
 
 
 
 
 
 
 
 
 
Total
12,629
100
12
14
6,275
100
8
11
 
Table 8: Top-ten medicines by Total Revenue
 
Medicine
Therapy Area
H1 2020
Q2 2020
$m
% of total
% change
$m
% change
Actual
CER
Actual
CER
Tagrisso
Oncology
2,016
16
43
45
1,034
32
35
Symbicort
Respiratory & Immunology
1,442
11
23
26
653
12
15
Imfinzi
Oncology
954
8
51
52
492
46
48
Lynparza
Oncology
951
8
64
66
554
62
65
Farxiga
CVRM
850
7
17
21
444
17
23
Brilinta
CVRM
845
7
15
17
437
12
16
Nexium
Other medicines
731
6
(5)
(3)
384
(4)
(1)
Crestor
CVRM
583
5
(10)
(7)
282
(9)
(6)
Zoladex
Oncology
484
4
22
27
257
28
34
Pulmicort
Respiratory & Immunology
477
4
(33)
(32)
97
(71)
(69)
 
 
 
 
 
 
 
 
 
Total
 
9,333
74
20
22
4,634
14
17
 
Table 9: Collaboration Revenue
Other Ongoing Collaboration Revenue included Zoladex, Farxiga, Eklira, Nexium OTC24 and other royalties. No Initial Collaboration Revenue was recorded in the half.
 
 
H1 2020
Q2 2020
$m
% of total
% change
$m
% change
Actual
CER
Actual
CER
Lynparza: regulatory milestone revenue
135
50
n/m
n/m
135
n/m
n/m
Enhertu: profit share
36
13
n/m
n/m
22
n/m
n/m
Roxadustat: profit share
11
4
n/m
n/m
9
n/m
n/m
Other Collaboration Revenue
88
33
24
25
61
36
36
 
 
 
 
 
 
 
 
Total
270
100
n/m
n/m
227
n/m
n/m
Total Revenue
 
The performance of the Company’s medicines is shown below, with a geographical split of Product Sales shown in Note 7.
 
Table 10: Therapy area and medicine performance - H1 2020
 
 
Product Sales: therapy area
Medicine
H1 2020
$m
% of total Product Sales
% change
Actual
CER
Oncology
Tagrisso
2,016
16
43
45
Imfinzi
954
8
51
52
Lynparza
816
7
57
60
Calquence
195
2
n/m
n/m
Koselugo
7
-
n/m
n/m
Zoladex
442
4
13
18
Faslodex
312
3
(40)
(38)
Iressa
147
1
(42)
(40)
Arimidex
107
1
(3)
-
Casodex
89
1
(15)
(13)
Others
26
-
(50)
(47)
Total Oncology
5,111
41
26
28
BioPharmaceuticals: CVRM
Farxiga
848
7
17
21
Brilinta
845
7
15
17
Onglyza
256
2
(5)
(3)
Bydureon
216
2
(24)
(23)
Byetta
35
-
(36)
(35)
Other diabetes
23
-
3
6
Lokelma
28
-
n/m
n/m
Crestor
582
5
(10)
(8)
Seloken/Toprol-XL
395
3
-
6
Atacand
126
1
19
25
Others
106
1
(20)
(18)
BioPharmaceuticals:
total CVRM
3,460
28
3
6
BioPharmaceuticals: Respiratory & Immunology
Symbicort
1,442
12
23
26
Pulmicort
477
4
(33)
(32)
Fasenra
426
3
44
45
Daliresp/Daxas
106
1
1
2
Bevespi
22
-
10
10
Breztri
11
-
n/m
n/m
Others
184
1
(20)
(18)
BioPharmaceuticals: total Respiratory & Immunology
2,668
22
5
7
Other medicines
Nexium
714
6
(5)
(3)
Synagis
176
1
18
18
Losec/Prilosec
99
1
(32)
(30)
Seroquel XR/IR
63
1
(9)
(8)
Others
68
1
(32)
(31)
Total other medicines
1,120
9
(8)
(6)
 
Total Product Sales
12,359
100
11
13
 
Total Collaboration Revenue
270
 
n/m
n/m
 
Total Revenue
12,629
 
12
14
 
Table 11: Therapy area and medicine performance - Q2 2020
 
Product Sales: therapy area
Medicine
Q2 2020
$m
% of total Product Sales
% change
Actual
CER
Oncology
Tagrisso
1,034
17
32
35
Imfinzi
492
8
46
48
Lynparza
419
7
48
52
Calquence
107
2
n/m
n/m
Koselugo
7
-
n/m
n/m
Zoladex
217
4
10
17
Faslodex
146
2
(45)
(43)
Iressa
70
1
(41)
(38)
Arimidex
58
1
(4)
-
Casodex
47
1
(17)
(15)
Others
12
-
(59)
(55)
Total Oncology
2,609
43
20
24
BioPharmaceuticals: CVRM
Farxiga
443
7
17
23
Brilinta
437
7
12
16
Onglyza
115
2
(1)
3
Bydureon
116
2
(18)
(17)
Byetta
15
-
(42)
(41)
Other diabetes
10
-
(9)
(5)
Lokelma
17
-
n/m
n/m
Crestor
281
5
(10)
(6)
Seloken/Toprol-XL
218
4
29
38
Atacand
59
1
6
14
Others
48
1
(23)
(20)
BioPharmaceuticals:
total CVRM
1,759
29
6
10
BioPharmaceuticals: Respiratory & Immunology
Symbicort
653
11
12
15
Pulmicort
97
2
(71)
(69)
Fasenra
227
4
36
37
Daliresp/Daxas
53
1
(7)
(7)
Bevespi
10
-
(1)
(3)
Breztri
7
-
n/m
n/m
Others
70
1
(30)
(28)
BioPharmaceuticals: total Respiratory & Immunology
1,117
18
(11)
(8)
Other medicines
Nexium
377
6
(4)
(1)
Synagis
90
1
(5)
(5)
Losec/Prilosec
45
1
(34)
(31)
Seroquel XR/IR
27
-
(16)
(14)
Others
24
-
(53)
(52)
Total other medicines
563
9
(12)
(10)
 
Total Product Sales
6,048
100
6
9
 
Total Collaboration Revenue
227
 
n/m
n/m
 
Total Revenue
6,275
 
8
11
 
Total Revenue summary
 
Oncology
Total Revenue of $5,324m in the half; an increase of 28% (31% at CER). This included Lynparza Collaboration Revenue of $135m. The performance of Enhertu was reflected entirely in Collaboration Revenue.
 
Oncology represented 42% of overall Total Revenue (H1 2019: 37%).
 
Tagrisso
Tagrisso has received regulatory approval in 86 countries, including the US, China, in the EU and Japan for the 1st-line treatment of patients with EGFRm NSCLC. To date, reimbursement has been granted in 28 countries in this setting, with further reimbursement decisions anticipated in the second half of the year. This followed Tagrisso’s initial approval in 89 countries, including the US, China, in the EU and Japan for the treatment of patients with EGFR T790M25-mutated NSCLC.
 
Total Revenue, entirely comprising Product Sales, amounted to $2,016m in the half and represented growth of 43% (45% at CER). This was partly driven by the aforementioned regulatory approvals and reimbursements in the 1st-line setting. Continued growth was also delivered in the 2nd-line setting, for example, within Europe and Emerging Markets. Sales in the US increased by 30% to $725m, despite adverse inventory movements in the second quarter. Demand growth continued as Tagrisso retained its position as the standard of care (SoC) in the 1st-line setting.
 
In Emerging Markets, Tagrisso sales increased by 81% in the half (89% at CER) to $595m, with notable growth in China, following the admission in 2019 to the China National Drug Reimbursement List (NRDL) in the 2nd-line setting. Tagrisso Total Revenue in Japan increased by 17% (16% at CER) to $340m. In Europe, sales of $325m in the half represented an increase of 53% (58% at CER), driven by its use in the 1st-line setting, as more reimbursements were granted.
 
Imfinzi
Imfinzi has received regulatory approval in 62 countries, including the US, China, in the EU and Japan for the treatment of patients with unresectable, Stage III NSCLC whose disease has not progressed following platinum-based chemoradiation therapy (CRT). The number of reimbursements increased to 27 in the half. During the period, Imfinzi was also approved for the treatment of ES-SCLC patients in eight countries, including the US. It is already approved for the 2nd-line treatment of patients with locally advanced or metastatic urothelial carcinoma (bladder cancer) in 17 countries, including the US.
 
Total Revenue, entirely comprising Product Sales, amounted to $954m in the half and represented growth of 51% (52% at CER), predominantly for the treatment of unresectable, Stage III NSCLC. Total Revenue in the US increased by 21% to $574m; in Japan, growth of 44% (43% at CER) represented sales of $124m. Sales in Europe increased by 179% (188% at CER) to $167m, reflecting a growing number of reimbursements, while sales in Emerging Markets increased by 428% (459% at CER) to $63m, following recent regulatory approvals and launches.
 
Lynparza
Lynparza has received regulatory approval in 75 countries for the treatment of ovarian cancer; it has also been approved in 67 countries for the treatment of metastatic breast cancer, and in 38 countries, including the US, for the treatment of pancreatic cancer. Finally, it has also received regulatory approval in the US for the 2nd-line treatment of HRRm prostate cancer.
 
Total Revenue amounted to $951m in the half and represented growth of 64% (66% at CER); $135m of Lynparza Collaboration Revenue, reflecting regulatory-milestone receipts, was recorded in the half. The strong performance was geographically spread, with launches continuing in Emerging Markets and the Established Rest of World region (RoW).
 
US sales increased by 55%, driven by the launch in the 1st-line BRCAm ovarian cancer setting at the end of 2018. Lynparza continued to be the leading medicine in the poly ADP ribose polymerase (PARP)-inhibitor class, as measured by total prescription volumes in both ovarian and breast cancer. Sales in Europe increased by 51% (56% at CER) to $198m, reflecting increasing levels of reimbursement and BRCAm-testing rates, as well as successful recent 1st-line ovarian cancer launches, including in the UK and Germany.
 
Japan sales of Lynparza amounted to $77m, representing growth of 32% (31% at CER). Emerging Markets sales of $120m, up by 104% (117% at CER), were a result of the regulatory approval of Lynparza as a 2nd-line maintenance treatment of patients with ovarian cancer by the China National Medical Products Administration (NMPA) in 2019. Lynparza was admitted to the China NRDL for the same indication, with effect from January 2020.
 
Enhertu
Global sales, recorded by Daiichi Sankyo, amounted to $77m. This reflected sales predominantly in the US, where Enhertu was launched at the start of the year and where Daiichi Sankyo is the principal. Enhertu was approved by the US Food and Drug Administration (FDA) for the treatment of 3rd-line HER2+ breast cancer at the end of 2019. Total Revenue, entirely comprising Collaboration Revenue recorded by AstraZeneca, amounted to $36m in the half.
 
Calquence
Total Revenue, entirely comprising Product Sales, amounted to $195m in the half and represented growth of 204% (205% at CER), with the overwhelming majority of sales in the US. Calquence was approved by the US FDA for the treatment of CLL and small lymphocytic lymphoma in November 2019 and received regulatory approval in this indication in an additional 12 countries. Calquence has also received 17 other regulatory approvals for the treatment of patients with mantle cell lymphoma.
 
Koselugo
Total Revenue, entirely comprising Product Sales in the US, amounted to $7m in the half, following its launch during the period. Koselugo was approved by the US FDA for the treatment of paediatric patients aged two years and older with NF1 who have symptomatic, inoperable plexiform neurofibromas.
 
Legacy: Zoladex
Total Revenue, predominantly comprising Product Sales, amounted to $484m in the half and represented growth of 22% (27% at CER).
 
Emerging Markets sales of Zoladex increased by 22% (29% at CER) to $288m reflecting increased use and access in prostate cancer. Sales in Europe increased by 5% (8% at CER) to $68m. In the Established RoW region, sales declined by 7% (6% at CER) to $81m, driven by the effects of increased competition.
 
Legacy: Faslodex
Total Revenue, entirely comprising Product Sales, amounted to $312m in the half and represented a decline of 40% (38% at CER).
 
Emerging Markets sales of Faslodex increased by 4% (10% at CER) to $100m. US sales, however, declined by 87% to $34m, reflecting the launch in 2019 of multiple generic Faslodex medicines. In Europe, where generic competitor medicines are established, sales increased by 6% (9% at CER) to $116m, while in Japan, sales declined by 5% (7% at CER) to $58m, driven by a mandated price reduction in the second quarter.
 
Legacy: Iressa
Total Revenue, entirely comprising Product Sales, amounted to $147m in the half and represented a decline of 42% (40% at CER). Sales in Emerging Markets declined by 27% (24% at CER) to $120m, reflecting the growing impact of Iressa’s inclusion on the China volume-based procurement programme.
 
BioPharmaceuticals: CVRM
Total Revenue increased by 3% in the first half (6% at CER) to $3,478m and represented 28% of Total Revenue (H1 2019: 30%). This included roxadustat Ongoing Collaboration Revenue of $11m, as well as sales of Crestor and other legacy medicines.
 
New CVRM Total Revenue, which excludes sales of Crestor and other legacy medicines, increased by 8% in the half (11% at CER) to $2,265m, reflecting the performances of Farxiga and Brilinta. New CVRM represented 65% of overall CVRM Total Revenue in the half (H1 2019: 62%).
 
Farxiga
Total Revenue, predominantly comprising Product Sales, amounted to $850m in the half and represented growth of 17% (21% at CER).
 
Emerging Markets sales increased by 49% (59% at CER) to $306m. In China, Farxiga was admitted to the NRDL with effect from the start of 2020; as expected, this adversely impacted pricing. This effect, however, was more than offset by the volume benefit derived from the launch within the NRDL listing. The performance also reflected continued growth in the sodium-glucose layer transport protein 2 inhibitor class at the expense of the dipeptidyl-peptidase 4 (DPP-4) inhibitor class.
 
US sales declined by 12% to $237m, reflecting the impact of competitive activity on pricing and the mix of channel sales that outweighed an encouraging level of volume growth. There were, however, favourable movements in the share of new-to-brand prescriptions, a result of a label update in Q3 2019 to reflect results from the DECLARE CVOT and the more recent HF (with reduced ejection fraction) label.
 
Sales in Europe increased by 25% (29% at CER) to $223m, partly reflecting growth in the class and an acceleration of new-to-brand prescriptions, following a similar DECLARE-trial label update. In Japan, sales to the collaborator, Ono Pharmaceutical Co., Ltd, which records in-market sales, increased by 14% (12% at CER) to $43m.
 
Brilinta
Total Revenue, entirely comprising Product Sales, amounted to $845m in the half and represented growth of 15% (17% at CER). Patient uptake continued in the treatment of acute coronary syndrome and high-risk post-myocardial infarction (MI).
 
Emerging Markets sales increased by 34% (40% at CER) to $291m. US sales, at $351m, represented an increase of 9%, driven primarily by increasing levels of demand in both hospital and retail settings, as well as a lengthening in the average-weighted duration of treatment, reflecting the growing impact of 90-day prescriptions. Sales of Brilique in Europe increased by 2% in the half (5% at CER) to $173m, mainly reflecting performances in Germany, France and Italy.
 
Onglyza
Total Revenue, entirely comprising Product Sales, amounted to $256m in the half and represented a decline of 5% (3% at CER).
 
Sales in Emerging Markets increased by 15% (21% at CER) to $100m, driven by the performance in China. US sales of Onglyza declined by 12% in the half to $105m; Europe sales declined by 21% (18% at CER) to $29m. This highlighted the broader trend of a shift away from the DPP-4 inhibitor class. Given the significant future potential of Farxiga, the Company continues to prioritise commercial support over Onglyza.
 
Bydureon
Total Revenue, entirely comprising Product Sales, amounted to $216m in the half and represented a decline of 24% (23% at CER).
 
US sales of $185m reflected a decline of 21% in the half, resulting from competitive pressures and the impact of managed markets. Patients continue to transition from the dual-chamber pen to the BCise device. Bydureon sales in Europe fell by 29% (26% at CER) to $24m. Reflecting the recent and potential performance of Bydureon, a $102m intangible-asset impairment charge was recorded in the half.
 
Qternmet
During the period, the Company decided not to progress with the planned launch of Qternmet (a fixed-dose combination of metformin, Farxiga and Onglyza), reflecting adverse changes in the competitive landscape.
 
Lokelma
Total Revenue, entirely comprising Product Sales, amounted to $28m in the half. Q2 2020 sales of $17m reflected sequential growth of 56% (58% at CER) over Q1 2020.
 
The US represented the overwhelming majority of sales, following the recent launch of the medicine; Lokelma led new-to-brand prescription market share during the period. The medicine has received regulatory approval in a number of markets including in the EU, China and Japan and for the treatment of hyperkalaemia, with further launches in several markets anticipated soon.
 
Roxadustat
Total Revenue, entirely comprising Ongoing Collaboration Revenue, amounted to $11m in the half. The period saw a continued focus on achieving hospital listings across China, with more than 40,000 patients being treated for anaemia in CKD with the medicine. The China NMPA approved roxadustat for the treatment of anaemia in CKD in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients in December 2018 and August 2019, respectively. Roxadustat was admitted to the China NRDL with effect from January 2020.
 
In China, the Company currently records its share of roxadustat gross profit as Collaboration Revenue. During the period, FibroGen and AstraZeneca entered into an amendment, effective 1 July 2020, to revise the existing licence, development and commercialisation agreement that was originally entered into on 30 July 2013, relating to the development and commercialisation of roxadustat in China. The amendment establishes a jointly owned entity that, once fully operational in 2021, will mean that FibroGen is expected to recognise revenue based on its sales to the entity, whereas AstraZeneca will likely recognise the overwhelming majority of its future revenue in China as Product Sales.
 
Legacy: Crestor
Total Revenue, predominantly comprising Product Sales, amounted to $583m in the half and represented a decline of 10% (7% at CER).
 
Sales in Emerging Markets declined by 9% (6% at CER) to $369m. The performance was adversely impacted by the effect of volume-based procurement in China. US sales declined by 17% to $45m. In Europe, sales declined by 13% (12% at CER) to $65m while in Japan, where AstraZeneca collaborates with Shionogi Co., Ltd, sales declined by 5% (6% at CER) to $81m.
 
BioPharmaceuticals: Respiratory & Immunology
Total Revenue increased by 5% in the half (7% at CER) to $2,676m and represented 21% of Total Revenue (H1 2019: 22%). This included Ongoing Collaboration Revenue of $8m from Duaklir, Eklira and Siliq.
 
Symbicort
Total Revenue, entirely comprising Product Sales, amounted to $1,442m in the half and represented growth of 23% (26% at CER).
 
US sales grew by 46% to $558m in the half. An authorised-generic version of Symbicort was launched in the US by the Company’s collaborator, Prasco, in January 2020. Symbicort also continued its global market-volume and value leadership within the inhaled corticosteroid / long-acting beta agonist (LABA) class. Emerging Markets sales increased by 10% in the half (16% at CER) to $290m, reflecting particularly strong performances in China and the Middle East & Africa.
 
In Europe, sales increased by 1% in the half (4% at CER) to $356m. In Japan, sales increased by 53% (51% at CER) to $102m, supported by the continued effect of AstraZeneca regaining full rights, following termination in 2019 of the Astellas co-promotion agreement; the increase was despite the market entry of a generic medicine.
 
Pulmicort
Total Revenue, entirely comprising Product Sales, amounted to $477m in the half and represented a decline of 33% (32% at CER).
 
Emerging Markets, where Pulmicort sales declined by 36% in the half (34% at CER) at $371m, represented 78% of global total. The performance in China continued to be impacted by COVID-19, with a significant reduction in the number of paediatric patients attending outpatient nebulisation rooms and adult elective procedures, where Pulmicort can be used in operative care when oral corticosteroids are unsuitable. This was particularly evident in the second quarter, when Pulmicort sales in Emerging Markets declined by 78% (76% at CER) to $58m. The declines were also a reflection of a particularly benign influenza season in China, resulting in a significantly reduced number of asthma exacerbations.
 
Sales in the US declined by 36% to $36m, while they fell in Europe by 8% (4% at CER) to $40m.
 
Fasenra
Fasenra has received regulatory approval in 58 countries, including in the US, the EU and Japan for the treatment of patients with severe, uncontrolled eosinophilic asthma. With further regulatory reviews ongoing, Fasenra has already achieved reimbursement in 41 countries. Total Revenue, entirely comprising Product Sales, amounted to $426m in the half and represented growth of 44% (45% at CER).
 
Sales in the US increased by 31% in the half to $272m, supported by an increase in the self-administration use as a result of COVID-19 restrictions. For the aforementioned treatment of patients, Fasenra ended the half as the leading novel biologic medicine in the US, as measured by new-to-brand prescriptions. In Europe, sales of $88m in the half represented an increase of 96% (102% at CER), reflecting a number of successful launches. Sales in Japan increased by 21% (20% at CER) to $46m. In its approved indication and among new patients, Fasenra obtained the leading market share of all novel biologic medicines in the ‘top-five’ European countries and in Japan. In Emerging Markets, sales amounted to $7m in the half (H1 2019: $1m).
 
Daliresp/Daxas
Total Revenue, entirely comprising Product Sales, amounted to $106m in the half and represented an increase of 1% (2% at CER).
 
US sales, representing 85% of the global total, increased by 1% to $90m, driven by higher demand.
 
Bevespi
Total Revenue, entirely comprising Product Sales, amounted to $22m in the half and represented an increase of 10%.
 
Bevespi has been launched in the US, in a number of European countries and in Japan. The global LABA / long acting muscarinic antagonist class continued to grow more slowly than expected.
 
Breztri
Total Revenue, entirely comprising Product Sales, amounted to $11m in the half (H1 2019: $nil).
 
Following successful launches in Japan and China for the treatment of COPD, Breztri was recently approved in the US.
 
Other medicines (outside the three main therapy areas)
Total Revenue, primarily comprising Product Sales, amounted to $1,151m in the half, representing a decline of 8% (6% at CER). The performance partly reflected the divestment of global rights to Movantik, excluding Europe, Canada and Israel, to RedHill Biopharma in April 2020. Other Total Revenue represented 9% of overall Total Revenue (H1 2019: 11%).
 
Nexium
Total Revenue, predominantly comprising Product Sales, amounted to $731m in the half; a decline of 5% (3% at CER). Emerging Markets sales of Nexium were stable (increasing by 4% at CER) at $370m. In Europe, sales increased by 20% (25% at CER) to $38m, while sales in the US declined by 30% to $89m and in Japan, where AstraZeneca collaborates with Daiichi Sankyo, they fell by 5% to $204m.
 
Losec/Prilosec
Total Revenue, entirely comprising Product Sales, amounted to $99m in the half, a decline of 32% (30% at CER). Sales in Emerging Markets declined by 15% (12% at CER) to $81m. Sales in Europe fell by 68% to $10m, while in Japan, they declined by 45% (46% at CER) to $5m.
 
Synagis
The commercial rights to the sale and distribution of Synagis outside the US, held by AbbVie, Inc (AbbVie) since 1997, will revert to AstraZeneca upon the expiry of the current agreement on 30 June 2021. In general, the Company will solely distribute and promote the medicine outside the US from 1 July 2021. The agreement with Swedish Orphan Biovitrum AB (publ), for the rights to Synagis in the US, was unaffected by this decision.
 
Regional Total Revenue
 
Table 12: Regional Total Revenue
 
H1 2020
Q2 2020
$m
% of total
% change
$m
% change
Actual
CER
Actual
CER
Emerging Markets
4,329
34
9
15
2,056
6
13
China         
2,659
21
10
14
1,243
7
12
 Ex-China         
1,671
13
8
15
813
4
15
 
 
 
 
 
 
 
 
US
4,177
33
13
13
2,085
10
10
 
 
 
 
 
 
 
 
Europe
2,447
19
17
20
1,244
12
15
 
 
 
 
 
 
 
 
Established RoW
1,676
13
7
7
890
2
3
Japan         
1,232
10
3
2
679
(2)
(3)
Canada         
298
2
33
35
143
28
35
Other Established RoW          
145
1
2
10
68
6
17
 
 
 
 
 
 
 
 
Total
12,629
100
12
14
6,275
8
11
 
Table 13: Emerging Markets therapy-area performance - Total Revenue
 
 
H1 2020
Q2 2020
$m
% of total
% change
$m
% change
Actual
CER
Actual
CER
Oncology
1,461
34
39
46
750
34
43
BioPharmaceuticals
1,480
34
-
5
608
(15)
(9)
           New CVRM          
719
17
38
46
387
37
48
                        Respiratory & Immunology         
761
18
(20)
(17)
221
(49)
(45)
Other medicines
1,389
32
(3)
2
697
4
11
 
 
 
 
 
 
 
 
Total
4,329
100
9
15
2,056
6
13
Table 14: Notable new-medicine performances in Emerging Markets - Total Revenue
 
H1 2020
Q2 2020
$m
% of total
% change
$m
% change
Actual
CER
Actual
CER
Tagrisso
595
14
81
89
315
65
74
Forxiga
306
7
49
59
165
49
62
Brilinta
291
7
34
40
156
30
39
Lynparza26
120
3
n/m
n/m
64
95
n/m
 
The new medicines represented 32% of Emerging Markets Total Revenue (H1 2019: 20%). Total Revenue from specialty-care medicines increased by 40% (47% at CER) to $1,771m and comprised 41% of Emerging Markets sales in the half (H1 2019: 32%).
 
China Total Revenue, which included $11m of roxadustat Ongoing Collaboration Revenue, comprised 61% of Emerging Markets Total Revenue in the half and increased by 10% (14% at CER) to $2,659m. New-medicine Total Revenue in China, primarily driven by Tagrisso and Lynparza in Oncology and Brilinta and Forxiga in New CVRM, delivered particularly encouraging growth and represented 31% of China Total Revenue (H1 2019: 17%). This performance was supplemented by strong sales of Zoladex, Seloken and Symbicort, despite the disappointing performance from Pulmicort.
 
Ex-China Emerging Markets, comprising entirely of Product Sales, increased by 8% in the half (15% at CER) to $1,671m. The new medicines represented 34% of ex-China Emerging Markets Total Revenue in the half (H1 2019: 27%), increasing by 39% (48% at CER) to $572m. The performance was underpinned by strong levels of growth across the following:
 
Table 15: Ex-China Emerging Markets: Total Revenue
 
 
H1 2020
Q2 2020
$m
% change
$m
% change
Actual
CER
Actual
CER
Ex-China Asia Pacific
597
5
7
286
(1)
2
Middle East and Africa
530
10
12
266
9
12
Ex-Brazil Latin America
206
(2)
14
98
(10)
11
Russia
175
57
67
91
45
68
Brazil
161
(6)
16
72
(6)
28
 
Financial performance
 
Table 16: Reported Profit and Loss - H1 2020
 
 
H1 2020
H1 2019
% change
$m
$m
Actual
CER
Total Revenue
12,629
11,314
12
14
                                                                      Product Sales
12,359
11,183
11
13
                                                      Collaboration Revenue
270
131
n/m
n/m
 
 
 
 
 
Cost of Sales
(2,404)
(2,192)
10
15
 
 
 
 
 
Gross Profit
10,225
9,122
12
14
Gross Profit Margin
80.5%
80.4%
-
-
 
 
 
 
 
Distribution Expense
(191)
(159)
20
25
% Total Revenue
1.5%
1.4%
-
-
R&D Expense
(2,777)
(2,622)
6
7
% Total Revenue
22.0%
23.2%
+1
+1
SG&A Expense
(5,354)
(5,457)
(2)
-
% Total Revenue
42.4%
48.2%
+6
+6
 
 
 
 
 
Other Operating Income & Expense
601
706
(15)
(13)
% Total Revenue
4.8%
6.2%
-1
-1
 
 
 
 
 
Operating Profit
2,504
1,590
57
58
Operating Profit Margin
19.8%
14.1%
+6
+6
 
 
 
 
 
Net Finance Expense
(588)
(632)
(7)
(7)
Joint Ventures and Associates
(20)
(59)
(66)
(63)
 
 
 
 
 
Profit Before Tax
1,896
899
n/m
n/m
 
 
 
 
 
Taxation
(408)
(229)
78
76
Tax Rate
22%
25%
 
 
 
 
 
 
 
Profit After Tax
1,488
670
n/m
n/m
 
 
 
 
 
EPS
$1.17
$0.56
n/m
n/m
 
Table 17: Reported Profit and Loss - Q2 2020
 
 
Q2 2020
Q2 2019
% change
$m
$m
Actual
CER
Total Revenue
6,275
5,823
8
11
                                                                      Product Sales
6,048
5,718
6
9
                                                       Collaboration Revenue
227
105
n/m
n/m
 
 
 
 
 
Cost of Sales
(984)
(1,063)
(7)
3
 
 
 
 
 
Gross Profit
5,291
4,760
11
13
Gross Profit Margin
83.7%
81.4%
+2
+1
 
 
 
 
 
Distribution Expense
(104)
(81)
29
37
% Total Revenue
1.7%
1.4%
-
-
R&D Expense
(1,389)
(1,356)
2
4
% Total Revenue
22.1%
23.3%
+1
+1
SG&A Expense
(2,635)
(2,943)
(10)
(8)
% Total Revenue
42.0%
50.6%
+9
+8
 
 
 
 
 
Other Operating Income & Expense
121
113
7
19
% Total Revenue
1.9%
2.0%
-
-
 
 
 
 
 
Operating Profit
1,284
493
n/m
n/m
Operating Profit Margin
20.5%
8.5%
+12
+11
 
 
 
 
 
Net Finance Expense
(307)
(320)
(4)
(5)
Joint Ventures and Associates
(16)
(32)
(50)
(45)
 
 
 
 
 
Profit Before Tax
961
141
n/m
n/m
 
 
 
 
 
Taxation
(223)
(34)
n/m
n/m
Tax Rate
23%
24%
 
 
 
 
 
 
 
Profit After Tax
738
107
n/m
n/m
 
 
 
 
 
EPS
$0.58
$0.09
n/m
n/m
 
Table 18: Reconciliation of Reported Profit Before Tax to EBITDA - H1 2020
 
 
H1 2020
H1 2019
% change
$m
$m
Actual
CER
Reported Profit Before Tax
1,896
899
n/m
n/m
Net Finance Expense
588
632
(7)
(7)
Joint Ventures and Associates
20
59
(66)
(63)
Depreciation, Amortisation and Impairment
1,551
1,403
11
12
 
 
 
 
 
EBITDA
4,055
2,993
35
37
 
Table 19: Reconciliation of Reported Profit Before Tax to EBITDA - Q2 2020
 
 
Q2 2020
Q2 2019
% change
$m
$m
Actual
CER
Reported Profit Before Tax
961
141
n/m
n/m
Net Finance Expense
307
320
(4)
(5)
Joint Ventures and Associates
16
32
(50)
(45)
Depreciation, Amortisation and Impairment
710
727
(2)
-
 
 
 
 
 
EBITDA
1,994
1,220
63
63
 
Table 20: Reconciliation of Reported to Core financial measures - H1 202027
H1 2020
Reported
Restructuring
Intangible Asset Amortisation & Impairments
Diabetes Alliance
Other
Core
Core
% change
$m
$m
$m
$m
$m
$m
Actual
CER
Gross Profit
10,225
35
33
-
5
10,298
12
13
Gross Profit Margin
80.5%
 
 
 
 
81.1%
-
-1
 
 
 
 
 
 
 
 
 
Distribution Expense
(191)
-
-
-
-
(191)
20
25
R&D Expense
(2,777)
16
49
-
-
(2,712)
8
9
SG&A Expense
(5,354)
45
809
152
(5)
(4,353)
2
5
Total Operating Expenses
(8,322)
61
858
152
(5)
(7,256)
5
7
 
 
 
 
 
 
 
 
 
Other Operating Income & Expense
601
2
1
-
-
604
(15)
(13)
 
 
 
 
 
 
 
 
 
Operating Profit
2,504
98
892
152
-
3,646
21
23
Operating Profit Margin
19.8%
 
 
 
 
28.9%
+2
+2
 
 
 
 
 
 
 
 
 
Net Finance Expense
(588)
-
-
115
104
(369)
(5)
(7)
Taxation
(408)
(20)
(183)
(60)
(1)
(672)
26
28
 
 
 
 
 
 
 
 
 
EPS
$1.17
$0.06
$0.54
$0.16
$0.08
$2.01
24
26
 
Table 21: Reconciliation of Reported to Core financial measures - Q2 202028
 
Q2 2020
Reported
Restructuring
Intangible Asset Amortisation & Impairments
Diabetes Alliance
Other
Core
Core % change
$m
$m
$m
$m
$m
$m
Actual
CER
Gross Profit
5,291
16
16
-
-
5,323
11
12
Gross Profit Margin
83.7%
 
 
 
 
84.3%
+2
+1
 
 
 
 
 
 
 
 
 
Distribution Expense
(104)
-
-
-
-
(104)
29
37
R&D Expense
(1,389)
5
7
-
1
(1,376)
8
9
SG&A Expense
(2,635)
20
360
85
(6)
(2,176)
(1)
3
Total Operating Expenses
(4,128)
25
367
85
(5)
(3,656)
3
6
 
 
 
 
 
 
 
 
 
Other Operating Income & Expense
121
4
-
-
-
125
9
21
 
 
 
 
 
 
 
 
 
Operating Profit
1,284
45
383
85
(5)
1,792
32
31
Operating Profit Margin
20.5%
 
 
 
 
28.6%
+5
+4
 
 
 
 
 
 
 
 
 
Net Finance Expense
(307)
-
-
58
49
(200)
1
(3)
Taxation
(223)
(9)
(76)
(29)
(1)
(338)
68
68
 
 
 
 
 
 
 
 
 
EPS
$0.58
$0.03
$0.23
$0.09
$0.03
$0.96
32
31
Profit and Loss summary
 
a) 
Gross Profit
The increases in Reported and Core Gross Profit in the half reflected the growth in Product Sales. The Reported and Core Gross Profit Margins were stable at 81%; the Core Gross Profit Margin declined by one percentage point at CER, partly reflecting the impact of a one-off change in estimate relating to Group inventory valuation and the growth in profit share from the collaboration with MSD in respect of Lynparza. The Core Gross Profit Margin increased in the second quarter by two percentage points (one at CER) to 84%, reflecting the mix of Product Sales and manufacturing efficiencies.
 
b) 
Total Operating Expense
Reported Total Operating Expense increased by 1% in the half (3% at CER) to $8,322m and represented 66% of Total Revenue (H1 2019: 73%). Reported SG&A Expense was adversely impacted by an increased level of intangible asset impairments, including a $102m charge relating to Bydureon, and a $96m charge relating to Eklira/Tudorza and Duaklir, partially offset by a $95m impairment reversal in relation to FluMist. Core Total Operating Expense increased by 5% (7% at CER) to $7,256m and represented 57% of Total Revenue (H1 2019: 61%).
 
The increases partly reflected investment in the pipeline, including the development of Enhertu and the ending in 2019 of the release of the upfront funding of Lynparza development as part of the agreement with MSD; Core R&D Expense increased in the half by 8% (9% at CER) to $2,712m. The increase in Core Total Operating Expense was also driven by additional SG&A investment in Oncology-medicine launches and AstraZeneca’s further expansion in China; Core SG&A Expense increased in the half by 2% (5% at CER ) to $4,353m.
 
c) 
Other Operating Income and Expense29
Reported and Core Other Operating Income and Expense in the half included $350m of income that reflected an agreement to divest commercial rights to a number of legacy hypertension medicines, as well as the divestment of the rights to Inderal, Tenormin, Seloken and Omepral in Japan for $51m. Income from Allergan (part of AbbVie Inc) of $23m was also received in the half in respect of the development of brazikumab.
 
d) 
Net Finance Expense
The declines in Reported and Core Net Finance Expense partly reflected a favourable movement in loan interest, following the repayment of a $1bn bond in 2019.
 
e) 
Taxation
The Reported and Core Tax Rates for the half were 22% and 21% respectively (H1 2019: 25% and 21% respectively). The net cash tax paid for the half was $792m, representing 42% of Reported Profit Before Tax (H1 2019: $723m, 80%).
 
f) 
EPS
Reported EPS of $1.17 in the half represented an increase of 108% (106% at CER); Core EPS increased by 24% (26% at CER) to $2.01. This was despite an increase in the weighted-average number of shares to 1,312m (H1 2019: 1,289m).
 
g) 
Dividends
The Board has recommended an unchanged first interim dividend of $0.90 (69.6 pence, 7.87 SEK) per Ordinary Share.
 
Table 22: Cash Flow
 
H1 2020
H1 2019
Change
$m
$m
$m
Reported Operating Profit
2,504
1,590
914
Depreciation, Amortisation and Impairment
1,551
1,403
148
 
 
 
 
Increase in Working Capital and Short-Term Provisions
(780)
(634)
(146)
Gains on Disposal of Intangible Assets
(411)
(590)
179
Non-Cash and Other Movements
(555)
(177)
(378)
Interest Paid
(338)
(378)
40
Taxation Paid
(792)
(723)
(69)
 
 
 
 
Net Cash Inflow from Operating Activities
1,179
491
688
 
 
 
 
Net Cash Inflow/(Outflow) Before Financing Activities
1,336
(298)
1,634
 
 
 
 
Net Cash (Outflow)/Inflow from Financing Activities
(1,236)
941
(2,177)
 
The increase in Net Cash Inflow from Operating Activities in the half primarily reflected an underlying improvement in business performance. The increase in Non-Cash and Other Movements of $378m to $555m was driven by a reduction in fair-value movements on business combination-related liabilities and included the effect of the re-acquisition of US rights to Duaklir/Tudorza from Circassia Pharmaceuticals plc (Circassia) in May 2020 in settlement of a loan receivable balance included in working capital.
 
The increase in Net Cash Inflow before Financing Activities was a result of the aforementioned improvement in Net Cash Inflow from Operating Activities, as well as a $931m increase in the Disposal of Non-Current Asset Investments to $949m; AstraZeneca sold an undisclosed proportion of its equity portfolio in the first half. Recorded within the Purchase of Intangible Assets, AstraZeneca made the second of two $675m upfront payments to Daiichi Sankyo as part of the 2019 agreement on Enhertu. There was a $313m reduction in the Purchase of Intangible Assets, versus H1 2019, to $983m.
 
The cash payment of contingent consideration, in respect of the former Bristol-Myers Squibb Company (BMS) share of the global diabetes alliance, amounted to $257m in the half.
 
The second interim dividend payment, amounting to $2,398m, was made in the period.
 
Capital Expenditure
Capital expenditure amounted to $370m in the half, compared to $438m in H1 2019. This included investment in the new AstraZeneca R&D centre on the Biomedical Campus in Cambridge, UK; total capital expenditure on the entire project to the end of June 2020 amounted to $993m (£787m, based on average exchange rates). It is too early to state the potential impact of ongoing COVID-19 restrictions and physical-distancing measures to the Cambridge construction schedule and project expenditure. The Company has made other progress on its transition to Cambridge, including the Anne McLaren Building on the Cambridge Biomedical Campus. As of the end of June 2020, over 3,300 colleagues were based in and around the city.
 
The Company anticipates a broadly stable level of total capital expenditure in FY 2020 (FY 2019: $979m).
 
Table 23: Net Debt summary
 
At 30 Jun 2020
At 31 Dec 2019
At 30 Jun 2019
$m
$m
$m
Cash and Cash Equivalents
5,673
5,369
5,428
Other Investments
442
911
875
 
 
 
 
Cash and Investments
6,115
6,280
6,303
 
 
 
 
Overdrafts and Short-Term Borrowings
(1,799)
(225)
(629)
Lease Liabilities
(639)
(675)
(720)
Current Instalments of Loans
(2,159)
(1,597)
(1,000)
Non-Current Instalments of Loans
(15,150)
(15,730)
(17,355)
 
 
 
 
Interest-Bearing Loans and Borrowings
(Gross Debt)
(19,747)
(18,227)
(19,704)
 
 
 
 
Net Derivatives
(18)
43
321
Net Debt
(13,650)
(11,904)
(13,080)
 
Net Debt increased by $1,746m in the half, principally due to Net Cash Inflow from Operating Activities of $1,179m being more than offset by the payment of the second interim dividend of 2019 of $2,398m (representing two thirds of the 2019 full year).
 
Details of the committed undrawn bank facilities are disclosed within the going-concern section of Note 1.
 
During the half, there were no changes to the Company’s credit ratings issued by Standard and Poor’s (long term: BBB+, short term A-2) and Moody’s (long term: A3, short term P-2).
 
Capital allocation
The Board’s aim is to continue to strike a balance between the interests of the business, financial creditors and the Company’s shareholders. After providing for investment in the business, supporting the progressive dividend policy and maintaining a strong, investment-grade credit rating, the Board will keep under review potential investment in immediately earnings-accretive, value-enhancing opportunities.
 
Foreign exchange
The Company’s transactional currency exposures on working-capital balances, which typically extend for up to three months, are hedged where practicable using forward foreign-exchange contracts against the individual companies’ reporting currency. Foreign-exchange gains and losses on forward contracts for transactional hedging are taken to profit or loss. In addition, the Company’s external dividend payments, paid principally in pounds sterling and Swedish krona, are fully hedged from announcement to payment date.
 
Table 24: Currency sensitivities
The Company provides the following currency-sensitivity information:
 
 
Average Exchange
Rates versus USD
 
Annual Impact of 5% Strengthening in Exchange Rate versus USD ($m)30
Currency
Primary Relevance
FY 201931
H1 202032
% change
Product Sales
Core Operating Profit
CNY
Product Sales
6.92
6.88
-
288
190
EUR
Product Sales
0.89
0.93
(4)
171
68
JPY
Product Sales
108.98
105.74
3
139
98
Other33
 
 
 
 
231
123
 
 
 
 
 
 
 
GBP
Operating Expense
0.78
0.81
(4)
27
(93)
SEK
Operating Expense
9.46
9.45
-
5
(51)
 
Related-party transactions
There have been no significant related-party transactions in the period.
 
Principal risks and uncertainties
It is not anticipated that the nature of the principal risks and uncertainties that affect the business (including the Company’s scientific and operational response to the COVID-19 pandemic), and which are set out on pages 74 to 77 of the Annual Report and Form 20-F Information 2019, will change in respect of the second six months of the financial year. The impact of COVID-19 on AstraZeneca’s operations is highly uncertain and cannot be predicted with confidence. The extent of any adverse impact on AstraZeneca’s operations (including the effects of any governmental or regulatory response to the pandemic) will depend on the global duration, extent and severity of the pandemic. To the extent the pandemic adversely affects AstraZeneca operations and/or performance, the Company expects it to have the effect of heightening certain risks, such as those relating to the delivery of the pipeline or launch of new medicines, the execution of AstraZeneca’s commercial strategy, the manufacturing and supply of medicines and reliance on third-party goods and services. The potential impact of Brexit continues to be treated as an integral part of the Principal Risks rather than as a stand-alone risk, as summarised on page 75 of the Annual Report and 20F information 2019.
 
In summary, the principal risks and uncertainties listed in the Annual Report and 20-F Information 2019 are:
 
1.
Medicine pipeline and intellectual property risks: failure or delay in delivery of pipeline and new medicines; failure to meet regulatory or ethical requirements for medicine development or approval; failure to obtain, defend and enforce effective intellectual property (IP) protection or IP challenges by third parties.
 
2.
Commercialisation risks: pricing, affordability, access and competitive pressures; failures or delays in quality execution of commercial strategies.
 
3.
Supply-chain and business-execution risks: failure to maintain supply of compliant, quality medicines; failure of information technology and data protection or cybercrime; failure to attract, develop, engage and retain a diverse, talented and capable workforce.
 
4.
Legal, regulatory and compliance risks: safety and efficacy of marketed medicines is questioned; adverse outcome of litigation and / or governmental investigations; failure to meet regulatory and ethical expectations on commercial practices, including bribery and corruption, and scientific exchanges.
 
5.
Economic and financial risks: failure to achieve strategic plans or meet targets or expectations.
 
Sustainability
 
AstraZeneca’s sustainability approach has three priority areas34, aligned with the Company’s purpose and business strategy:
 
-
Access to healthcare
 
-
Environmental protection
 
-
Ethics and transparency
 
Recent developments and progress against the Company’s priorities are reported below:
 
a) 
Access to healthcare
In April 2020, AstraZeneca signed a licence, development and distribution agreement with the University of Oxford for AZD1222. The Company also made several landmark agreements in the period, most notably, with BARDA and parallel agreements with the UK Government, Europe’s IVA, and CEPI, GAVI and the SII to supply low-and-middle-income countries.
 
In May 2020, AstraZeneca achieved the support of more than $1bn from BARDA for the development, production and delivery of the AZD1222 vaccine, starting in H2 2020. The development programme includes a Phase III clinical trial, with c.30,000 participants.
 
In June 2020, the Company announced a $750m agreement with CEPI and GAVI to support the manufacturing, procurement and distribution of 300 million doses of the vaccine, with delivery starting by the end of the year. Also, AstraZeneca reached a licensing agreement with the SII to supply one billion doses for low and middle-income countries, with a commitment to provide 400 million doses before the end of 2020. The agreement with CEPI and GAVI also represented the first advanced market commitment through the Access to COVID-19 Tools Accelerator, a global collaboration of philanthropic, multi-lateral, private sector and civil society partners.
 
The Company also announced in June 2020 that it had reached an agreement with Europe's IVA, spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the vaccine. The IVA aims to accelerate the supply of the vaccine and to make it available to other European countries that wish to participate in the initiative and is committed to providing equitable access to all participating countries across Europe. In July 2020, AstraZeneca announced agreements with R-Pharm in Russia and SK Biopharmaceuticals Co., Ltd in the Republic of Korea to manufacture and export for other global markets.
 
These agreements marked the latest commitments to support broad and equitable global access to the vaccine, particularly for low and middle-income countries. In aggregate, these parallel agreements have helped to provide a total manufacturing capacity of over two billion doses of the vaccine at no profit to AstraZeneca during the pandemic, in line with the aforementioned licence agreement with the University of Oxford.
 
During the period, AstraZeneca announced the signing of a Memorandum of Understanding with the Ministry of Health (MoH) of the Republic of Uganda for the expansion of the Company’s Healthy Heart Africa programme. The agreement will make Uganda the fifth country of implementation after Kenya, Ethiopia, Tanzania and Ghana. The partnership aims to strengthen the provision of services for managing and preventing hypertension, including raising awareness of lifestyle risk factors for CV disease, using MoH guidelines to standardise care, and upskilling health workers through training and education.
 
b) 
Environmental protection
In the period, the Solutions Journal published a 10-point action plan co-authored by Professor Jason Snape, Head of Environmental Protection, Global Sustainability, AstraZeneca. The action plan highlighted the strategies required for a more sustainable future post-pandemic and focused on the implementation of a circular bioeconomy. The article reflected the work of the Sustainable Markets Council, established by His Royal Highness, The Prince of Wales in September 2019, of which AstraZeneca and Pascal Soriot are founding council members.
 
In June 2020, The Prince of Wales launched The Great Reset with the World Economic Forum, a new global and multi-stakeholder call to action. The initiative will explore the necessary steps to recalibrate global systems in a post-pandemic world for a future that is more resilient, sustainable and inclusive. AstraZeneca actively supports progress towards a circular bioeconomy and The Great Reset as part of the Sustainable Markets Initiative and the need to operate responsibly and sustainably in the post-COVID-19 recovery.
 
During the period, Pascal Soriot was one of 176 business leaders13 from member companies of the Science-Based Targets initiative that signed a statement urging governments around the world to align their COVID-19 economic aid and recovery efforts with the latest climate science, which was announced by the UNGC in May 2020.
 
c) 
Ethics and transparency
Further highlighting the Company’s commitment to inclusion and diversity, AstraZeneca was recognised by DiversityInc as one of the 2020 Top 50 Companies for Diversity and the Company was also named as a Top Company for LGBT employees. In further recognition, Caireen Hargreaves, Associate Director, Product Sustainability, AstraZeneca, was awarded a position in the 2020 Top 50 Women in Engineering - Sustainability by the UK’s Women’s Engineering Society.
 
In July 2020, an interview was published by Reuters with AstraZeneca’s Executive Vice President, Human Resources, Fiona Cicconi. This focused on the additional measures implemented by the Company to support employees impacted by COVID-related gaps in children’s education and care provision. Measures included recruiting up to 80 teachers to run online lessons, providing personal tutoring and helping to locate some childcare spaces to ensure employees are able to focus and continue to develop and deliver life-changing medicines.
 
During the period, Heather Stewart, Vice President, Ethics & Transparency and Deputy Chief Compliance Officer, Global Sustainability spoke at a UNGC Deep Dive Insights kick-off webinar, as part of Workstream II Putting a Human Face to Climate Change of the Business Ambition for Climate and Health Action Platform, where the Company is Patron sponsor, which is developing a Human Rights Impact Guide for companies.
 
 

For more details on AstraZeneca’s sustainability ambition, approach and targets, please refer to the latest Sustainability Report 2019 and Sustainability Data Summary 2019. Additional information is available at astrazeneca.com/sustainability.
 

 
 
Research and development
 
As the COVID-19 pandemic develops, the Company will evaluate the impact on the initiation of clinical trials, ongoing recruitment and follow-ups. It is prudent to assume that some delays will arise as a consequence of the pandemic.
 
A comprehensive breakdown of AstraZeneca’s pipeline of medicines in human trials can be found in the latest clinical-trials appendix, available on astrazeneca.com. Highlights of developments in the Company’s late-stage pipeline since the prior results announcement are shown below:
 
Table 25: Late-stage pipeline
 
New molecular entities and major lifecycle events for medicines in Phase III trials or under regulatory review
17
Oncology
 
- Tagrisso - NSCLC
- Imfinzi - multiple cancers
-     Lynparza - multiple cancers
- Enhertu - multiple cancers
- capivasertib - breast cancer
- Calquence - blood cancers
- tremelimumab - multiple cancers
- savolitinib - NSCLC35363738
 
 
CVRM
 
- Farxiga - multiple indications
- roxadustat - anaemia in CKD
 
 
Respiratory & Immunology
 
- Fasenra - multiple indications
- PT010 - COPD
- PT027 - asthma
- tezepelumab - severe asthma
- nirsevimab - respiratory syncytial virus
- anifrolumab - lupus (SLE)
- brazikumab - inflammatory bowel disease43
Total projects
in clinical pipeline
142
 
 
Oncology
 
During the period, AstraZeneca presented new results across its broad portfolio of cancer medicines at the 2020 American Society of Clinical Oncology (ASCO20) Virtual Scientific Program, comprising 98 abstracts, including 19 oral presentations with one plenary and 10 late-breakers.
 
Presentations demonstrated the Company’s leadership in the treatment of early lung cancer, reflected by a late-breaking plenary presentation of the unprecedented results from the Phase III ADAURA trial for Tagrisso in the adjuvant treatment of patients with Stage IB, II and IIIA EGFRm NSCLC. Detailed results from an updated analysis of the Phase III CASPIAN trial were also presented where Imfinzi, in combination with a choice of chemotherapies, demonstrated a sustained, clinically meaningful overall survival (OS) benefit in ES-SCLC. Data from the DESTINY programme highlighted the potential of Enhertu across HER2-driven tumours, including lung, breast, gastric and colorectal cancers.
Oncology: lung cancer
 
a)
Tagrisso
During the ASCO20 Virtual Scientific Program, detailed results from the Phase III ADAURA trial were presented in a plenary session. Tagrisso demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) EGFRm NSCLC after complete tumour resection with curative intent. For the primary endpoint of DFS in patients with Stage II and IIIA disease, adjuvant treatment with Tagrisso reduced the risk of disease recurrence or death by 83% (hazard ratio [HR] 0.17; 95% confidence interval (CI) 0.12-0.23; p<0.0001). DFS results in the overall trial population, Stage IB through IIIA, a key secondary endpoint, demonstrated a reduction in the risk of disease recurrence or death of 79% (HR 0.21; 95% CI 0.16-0.28; p<0.0001). Consistent DFS results were seen across all subgroups, including patients who were treated with surgery followed by chemotherapy and those who received surgery only, as well as in Asian and non-Asian patients.
 
Table 26: Key Tagrisso trials in lung cancer
 
Trial
Population
Design
Timeline
Status
Phase III
NeoADAURA
Neo-adjuvant EGFRm
NSCLC
Placebo or Tagrisso
FPCD39
Q2 2020
 
First data anticipated
2021+
Recruitment
ongoing
Phase III
ADAURA
Adjuvant EGFRm NSCLC
Placebo or Tagrisso
FPCD
Q4 2015
 
LPCD40
Q1 2019
Trial unblinded early due to overwhelming efficacy
Phase III
LAURA
Locally advanced, unresectable EGFRm NSCLC
Placebo or Tagrisso
FPCD
Q4 2018
 
First data anticipated
2021+
Recruitment
ongoing
Phase III
FLAURA2
1st-line EGFRm NSCLC
Tagrisso or Tagrisso + platinum-based chemotherapy doublet
FPCD
Q4 2019
 
First data anticipated
2021+
Recruitment ongoing
 
b) 
Imfinzi
Detailed results from an updated analysis of the Phase III CASPIAN Imfinzi trial were presented at the ASCO20 Virtual Scientific Program. Imfinzi, in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful OS benefit for adults with ES-SCLC. The CASPIAN trial had previously met the primary endpoint of OS in June 2019, which formed the basis of the US FDA approval in March 2020.
 
After a median follow-up of more than two years, the latest results for Imfinzi plus chemotherapy showed sustained efficacy, maintaining a 25% reduction in the risk of death versus chemotherapy alone (HR 0.75; 95% CI 0.62-0.91; nominal p=0.0032). Updated median OS was 12.9 months, versus 10.5 for chemotherapy.
 
During the period, the Company announced that Imfinzi had been recommended for marketing authorisation in the EU for the 1st-line treatment of adults with ES-SCLC in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin. The Committee for Medicinal Products for Human Use41 (CHMP) based its positive opinion on results from the Phase III CASPIAN trial for Imfinzi plus chemotherapy, which were also published in The Lancet.
 
Table 27: Key Imfinzi trials in lung cancer
 
Trial
Population
Design
Timeline
Status
Phase III
MERMAID-1
Stage II-III
resected NSCLC
SoC chemotherapy +/- Imfinzi
-
 
First data anticipated
2021+
Initiating
 
Phase III
AEGEAN
Neo-adjuvant (before surgery) NSCLC
SoC chemotherapy +/- Imfinzi,
followed by
surgery, followed by placebo or Imfinzi
FPCD
Q1 2019
 
First data anticipated
2021+
Recruitment
ongoing
Phase III
ADJUVANT BR.3142
Stage Ib-IIIa NSCLC
Placebo or
Imfinzi
FPCD
Q1 2015
 
LPCD
Q1 2020
 
First data anticipated
2021+
Recruitment
completed
Phase III
PACIFIC-2
Stage III unresected locally advanced NSCLC
(concurrent CRT)
Placebo or
Imfinzi
FPCD
Q2 2018
 
LPCD
Q3 2019
 
First data anticipated
H2 2020
Recruitment
completed
Phase III
ADRIATIC
Limited-
stage SCLC
Concurrent CRT,
followed by
placebo or
Imfinzi or Imfinzi + treme
FPCD
Q4 2018
 
First data anticipated
2021+
Recruitment
ongoing
Phase III
PEARL
Stage IV, 1st-line NSCLC
SoC chemotherapy or Imfinzi
FPCD
Q1 2017
 
LPCD
Q1 2019
 
First data anticipated
H1 2021
Recruitment
completed
Phase III
POSEIDON
Stage IV, 1st-line NSCLC
SoC chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
FPCD
Q2 2017
 
LPCD
Q4 2018
 
OS data anticipated
H2 2021
PFS43 primary endpoint met
Phase III
CASPIAN
ES-SCLC
SoC chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
FPCD
Q1 2017
 
LPCD
Q2 2018
OS primary endpoint met for Imfinzi monotherapy arm
 
OS primary endpoint not met for Imfinzi + treme
 
As a result of the positive Tagrisso ADAURA Phase III trial in the adjuvant treatment of EGFRm NSCLC, the impact on the Imfinzi ADJUVANT BR.31 Phase III trial analysis plan is currently being reviewed; data from this trial is anticipated in 2021+.
 
Table 28: Key Imfinzi trials in tumour types other than lung cancer
 
Trial
Population
Design
Timeline
Status
Phase III
POTOMAC
Non-muscle invasive bladder cancer
SoC BCG44 or SoC BCG + Imfinzi
FPCD
Q4 2018
 
First data
anticipated
2021+
Recruitment ongoing
Phase III
NIAGARA
Muscle-invasive bladder cancer
Neo-adjuvant cisplatin and gemcitabine SoC chemotherapy or SoC + Imfinzi, followed by adjuvant placebo or Imfinzi
FPCD
Q4 2018
 
First data
anticipated
H2 2021
Recruitment ongoing
Phase III
EMERALD-1
Locoregional HCC45
TACE46 followed by placebo or TACE + Imfinzi, followed by Imfinzi +
bevacizumab or
TACE + Imfinzi
followed by Imfinzi
FPCD
Q1 2019
 
First data
anticipated
H2 2021
Recruitment ongoing
Phase III
EMERALD-2
Locoregional HCC at high risk of recurrence after surgery or radiofrequency ablation
Adjuvant Imfinzi or Imfinzi + bevacizumab
FPCD
Q2 2019
 
First data anticipated
2021+
Recruitment ongoing
Phase III
CALLA
Locally advanced cervical cancer
CRT or CRT + Imfinzi, followed by placebo or Imfinzi
FPCD
Q1 2019
 
First data anticipated
2021+
Recruitment ongoing
Phase III
NILE
Stage IV, 1st-line cisplatin chemotherapy- eligible bladder cancer
SoC chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
FPCD
Q4 2018
 
First data anticipated
2021+
Recruitment
ongoing
Phase III
KESTREL
Stage IV, 1st-line HNSCC47
SoC or Imfinzi or Imfinzi + treme
FPCD
Q4 2015
 
LPCD
Q1 2017
 
First data
anticipated
H1 2021
Recruitment completed
Phase III
HIMALAYA
Stage IV, 1st-line unresectable HCC
Sorafenib or Imfinzi or Imfinzi + treme
FPCD
Q4 2017
 
LPCD
Q4 2019
 
First data
anticipated
H2 2020
Recruitment
completed
 
Orphan Drug Designation (US)48
Phase III
TOPAZ-1
Stage IV, 1st-line biliary-tract cancer
Gemcitabine and cisplatin SoC chemotherapy or SoC + Imfinzi
FPCD
Q2 2019
 
First data anticipated
H2 2021
Recruitment ongoing
 
c) 
Lynparza (multiple cancers)
During the period, AstraZeneca announced that Lynparza, in combination with bevacizumab, was approved in the US for the maintenance treatment of platinum-sensitive ovarian cancer patients whose cancer is associated with HRD-positive status. The approval by the US FDA was based on a subgroup analysis of the Phase III PAOLA-1 trial, which showed that Lynparza, in combination with bevacizumab maintenance treatment, reduced the risk of disease progression or death by 67% (equal to a hazard ratio of 0.33). The addition of Lynparza improved progression-free survival (PFS) to a median of 37.2 months, versus 17.7 months with bevacizumab alone in patients with HRD-positive advanced ovarian cancer.
 
During the period, AstraZeneca also announced that Lynparza had received regulatory approval in the US for patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). The approval was based on results from the Phase III PROfound trial, which were published in The New England Journal of Medicine. Lynparza demonstrated a radiographic PFS (rPFS) benefit in the overall HRR gene-mutated trial population, a key secondary endpoint, and reduced the risk of disease progression or death by 51% (equal to a hazard ratio of 0.49; p-value <0.0001) and improved rPFS to a median of 5.8 months, versus 3.5 months with enzalutamide or abiraterone.
 
Additional results from the PROfound trial, announced in April 2020, demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS with Lynparza versus enzalutamide or abiraterone in men with mCRPC and BRCA1/2 or Ataxia-Telangiectasia Mutated gene mutations. Results showed that Lynparza reduced the risk of death by 31% (equal to a hazard ratio of 0.69; p-value=0.0175) and improved OS to a median of 19.0 months, versus 14.6 months with enzalutamide or abiraterone.
 
During the period, the Company announced that Lynparza had been approved in the EU for patients with germline BRCAm (gBRCAm) metastatic pancreatic cancer, based on results from the Phase III POLO trial. The trial demonstrated that Lynparza nearly doubled the time patients with gBRCAm metastatic pancreatic cancer lived without disease progression or death to a median of 7.4 months, versus 3.8 months on placebo.
 
Table 29: Key Lynparza trials
 
Trial
Population
Design
Timeline
Status
Phase III
OlympiA
Adjuvant BRCAm breast cancer
SoC placebo or Lynparza
FPCD
Q2 2014
 
LPCD
Q2 2019
 
First data anticipated
H1 2021
Recruitment completed
 
Phase III
PROfound
Metastatic castration-resistant 2nd-line+ HRRm
prostate cancer
SoC (abiraterone or enzalutamide) or Lynparza
FPCD
Q2 2017
 
LPCD
Q4 2018
Primary endpoint met
 
Priority Review (US)
Phase III
PAOLA-149
Advanced 1st-line
ovarian cancer
Bevacizumab maintenance or
bevacizumab +
Lynparza maintenance
FPCD
Q2 2015
 
LPCD
Q2 2018
Primary endpoint met
 
Priority Review (US)
Phase II/III
GY005
Recurrent platinum-resistant/refractory ovarian cancer
SoC chemotherapy or cediranib or cediranib + Lynparza
FPCD
Q2 2016
(Phase II)
 
FPCD
Q1 2019
(Phase III)
 
First data
anticipated
2021+
Recruitment ongoing
(Phase III component)
Phase III
DuO-O
Advanced 1st-line
ovarian cancer
Chemotherapy +
bevacizumab or
chemotherapy +
bevacizumab +
Imfinzi +/-
Lynparza maintenance
 
FPCD
Q1 2019
 
First data
anticipated
2021+
Recruitment
ongoing
Phase III
DuO-E
Advanced 1st-line
endometrial cancer
Chemotherapy
or
chemotherapy +
Imfinzi + Imfinzi maintenance or
chemotherapy +
Imfinzi followed by Imfinzi + Lynparza maintenance
FPCD
Q2 2020
 
First data
anticipated
2021+
Recruitment
ongoing
Phase III
PROpel
Stage IV, advanced, castration-resistant prostate cancer
Abiraterone or
abiraterone +
Lynparza
FPCD
Q4 2018
 
First data
anticipated
H2 2021
Recruitment ongoing
Phase III
LYNK-003
Stage IV, 1st-line colorectal cancer
Bevacizumab + 5-FU maintenance or bevacizumab + Lynparza maintenance or Lynparza maintenance
First data
anticipated
2021+
Initiating
 
d) 
Enhertu (breast and other cancers)
During the period, the regulatory submission for Enhertu was accepted in the EU for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens. Enhertu was granted accelerated assessment by the CHMP. Daiichi Sankyo also announced a supplemental New Drug Application with expedited review by the Japan Ministry of Health, Labour and Welfare, based on SAKIGAKE-designation for Enhertu for the treatment of patients with HER2-positive metastatic gastric cancer.
 
During the period, key Enhertu data were presented at the ASCO20 Virtual Scientific Program in gastric cancer. Results from the positive, registrational, randomised controlled Phase II DESTINY-Gastric01 trial showed Enhertu demonstrated a statistically significant and clinically meaningful improvement in the objective response rate (ORR) of 42.9% and OS, a key secondary endpoint with a HR of 0.59 (95% CI 0.39-0.88; p=0.0097) versus chemotherapy. During the period, the US FDA awarded Breakthrough Therapy Designation to Enhertu for HER2-positive metastatic gastric cancer.
 
Enhertu also had results in lung and colorectal cancer at the ASCO20 Virtual Scientific Program. In lung cancer, data from the ongoing Phase II DESTINY-Lung01 trial showed Enhertu achieved a clinically meaningful tumour response in patients with HER2m unresectable and/or metastatic non-squamous NSCLC, whose disease had progressed following one or more systemic therapies with an ORR, assessed by independent central review of 61.9%. In colorectal cancer at the same meeting, results from the Phase II DESTINY-CRC01 trial demonstrated clinically meaningful activity in patients with HER2-positive unresectable and/or metastatic colorectal cancer who had received at least two prior lines of standard treatment, with 45.3% of patients achieving a tumour response. During the period, the US FDA awarded Breakthrough Therapy Designation to Enhertu for HER2m lung cancer.
 
Table 30: Key Enhertu trials
 
Trial
Population
Design
Timeline
Status
Phase II
DESTINY-Breast01
Stage IV, HER2+50 breast cancer post trastuzumab emtansine
Enhertu
(single arm)
FPCD
Q4 2017
 
LPCD
Q4 2018
Primary objective met
 
Breakthrough Therapy Designation (US)
 
Approval (JP), Accelerated Approval (US)
Phase III
DESTINY-Breast02
Stage IV, HER2+ breast cancer post trastuzumab emtansine
SoC chemotherapy or Enhertu
FPCD
Q4 2018
 
First data anticipated
H2 2021
Recruitment ongoing
Phase III
DESTINY-Breast03
Stage IV, HER2+ breast cancer
Trastuzumab emtansine or Enhertu
FPCD
Q4 2018
 
First data anticipated
H2 2021
Recruitment ongoing
Phase III
DESTINY-Breast04
Stage IV, HER2-low
SoC chemotherapy or Enhertu
FPCD
Q4 2018
 
First data anticipated
H2 2021
Recruitment ongoing
Phase II
DESTINY-Gastric01
Stage IV, HER2+ gastric cancer
SoC chemotherapy or Enhertu
FPCD
Q4 2017
 
LPCD
Q2 2019
Primary endpoint met
 
US Breakthrough Therapy Designation
Phase II
DPT02
HER2-expressing tumours
Enhertu
-
Initiating
 
e) 
Calquence
During the period, Calquence was recommended for marketing authorisation in the EU for the treatment of adult patients with CLL. The CHMP based its positive opinion on results from two Phase III clinical trials, ELEVATE TN in patients with previously untreated CLL, and ASCEND in patients with relapsed or refractory CLL.
 
f) 
Koselugo (NF1)
During the period, the Company announced that Koselugo (formerly selumetinib) was granted orphan drug designation in Japan for the treatment of NF1, following results from the Phase II SPRINT trial which demonstrated that Koselugo reduced tumour volume in paediatric patients with NF1 plexiform neurofibromas.
 
g) 
New collaboration to develop and commercialise new antibody drug conjugate
In July 2020, the Company announced that it had entered into a new global development and commercialisation agreement with Daiichi Sankyo for DS-1062, its proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate and potential new medicine for the treatment of multiple tumour types. DS-1062 is currently in development for the treatment of multiple tumours that commonly express the cell-surface glycoprotein TROP2. Among them, TROP2 is overexpressed in the majority of NSCLCs and breast cancers that have long been a strategic focus for AstraZeneca. The collaboration reflects AstraZeneca’s strategy to invest in antibody drug conjugates as a class, the innovative nature of the technology and the successful existing collaboration with Daiichi Sankyo.
 
h) 
Savolitinib (lung cancer)
During the period, Hutchison China MediTech Limited announced that the NMPA has granted Priority Review status to the new drug application for savolitinib for the treatment of NSCLC with MET Exon 14 skipping mutations. As per the original agreement announced in 2011, AstraZeneca will manufacture and commercialise savolitinib.
 
i) 
FKB238: bevacizumab biosimilar - (multiple cancers)
During the period, Centus Biotherapeutics Ltd., a joint venture between AstraZeneca and Fujifilm Kyowa Kirin Biologics Co., Ltd, announced that the CHMP had adopted a positive opinion for the Marketing Authorisation Application of FKB238, the companies’ Avastin bevacizumab biosimilar, for indications including metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent NSCLC, advanced and/or metastatic renal cell cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer, and persistent, recurrent, or metastatic carcinoma of the cervix.
 
CVRM
During the period, AstraZeneca presented new data from the Phase III DAPA-HF and DECLARE-TIMI 58 trials at the American Diabetes Association Virtual Conference. The data were among 23 accepted abstracts, including four oral presentations, covering trials across the Company’s cardio, renal and metabolic portfolio.
 
In June 2020, AstraZeneca presented new data across its broad portfolio of renal medicines at the 57th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress. The 20 abstracts presented, included four oral presentations for Lokelma, roxadustat and Farxiga, respectively, across different stages of CKD.
 
a) 
Farxiga (chronic kidney disease and heart failure)
In March 2020, the Company announced that the DAPA-CKD trial, which evaluated Farxiga in CKD, was stopped early due to overwhelming efficacy. In July 2020, AstraZeneca announced that the trial showed a statistically significant and clinically meaningful effect on its primary endpoint of a composite of worsening of renal function or risk of death (defined as a composite endpoint of ≥50% sustained decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease (ESRD) or CV or renal death) in adult patients with CKD. The trial also met all its secondary endpoints in CKD patients with and without T2D, making Farxiga the first medicine to significantly reduce the risk of death from any cause in this patient population. The full DAPA-CKD trial results will be presented at a forthcoming medical meeting.
 
In May 2020, the Company announced that the US FDA had approved Farxiga to reduce the risk of CV death and hospitalisation for HF in adults with HF (New York Heart Association class II-IV) with reduced ejection fraction with and without T2D. The approval was based on positive results from the landmark Phase III DAPA-HF trial, which showed Farxiga achieving a statistically significant and clinically meaningful reduction of CV death or hospitalisation for HF, compared to placebo.
 
In July 2020, the Company announced that the US FDA had granted Fast Track Designation for the development of Farxiga to reduce the risk of hospitalisation for heart failure or cardiovascular death in adults following an acute myocardial infarction (MI) or heart attack. The designation is based on the Phase III DAPA-MI trial that will explore the efficacy and safety of Farxiga in this patient population and is the first indication-seeking registry-based randomised controlled trial. The trial is expected to begin recruiting in the fourth quarter of 2020.
 
b) 
Brilinta (heart disease and stroke)
During the period, the US FDA approved Brilinta to reduce the risk of a first heart attack or stroke in high-risk patients with CAD, the most common type of heart disease. The approval was based on positive results from the Phase III THEMIS trial. The Company also decided to stop the HESTIA3 trial, which evaluated Brilinta for the prevention of vaso-occlusive crises in paediatric patients with sickle-cell disease. The decision was based on a recommendation from an Independent Data Monitoring Committee (IDMC), due to a low likelihood of demonstrating benefits that outweigh the risks.
 
In July 2020, the Company announced that the US FDA had accepted a supplemental New Drug Application and granted Priority Review designation for Brilinta for the reduction of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack. The PDUFA date is set for the fourth quarter of 2020. The Priority Review designation was based on data from the Phase III THALES trial. During the period, the Company also received regulatory submission acceptance in the EU for the same indication.
 
The full results from the THALES trial were published in The New England Journal of Medicine in July, showing that Brilinta 90mg used twice daily and taken with daily aspirin for 30 days, reduced the rate of the primary composite endpoint of stroke and death by 17% (HR 0.83 [95% CI 0.71-0.96], p=0.02), compared to aspirin alone in patients who had an acute ischemic stroke or transient ischemic attack.
 
Table 31: Key large CVRM outcomes trials
 
Trial
Population
Design
Primary endpoint(s)
Timeline
Status
Farxiga
 
Phase III
DAPA-HF
c.4,500 patients with HF with reduced ejection fraction, with and without T2D
Arm 1: Farxiga 10mg or 5mg QD51 + SoC
 
Arm 2: placebo + SoC
Time to first occurrence of CV death or hospitalisation due to HF or an urgent HF visit
FPCD
Q1 2017
 
LPCD
Q4 2018
Primary endpoint met
 
Fast Track designation (US)
Phase III
DELIVER
c.4,700 patients with HF and preserved ejection fraction, with and without T2D
Arm 1: Farxiga 10mg QD
 
Arm 2: placebo
Time to first occurrence of CV death or worsening HF
FPCD
Q4 2018
 
First data anticipatedH2 2021
 
Recruitment ongoing
 
Fast Track designation (US)
Phase III
DAPA-CKD
c.4,000 patients with CKD, with and without T2D
Arm 1: Farxiga 10mg or 5mg QD
 
Arm 2: placebo
Time to first occurrence of ≥ 50% sustained decline in eGFR or reaching ESRD or CV death or renal death
FPCD
Q1 2017
 
LPCD
Q1 2020
Trial stopped early based on recommendation from an IDMC
 
Primary endpoint and secondary endpoints met
 
 
Fast Track designation (US)
Brilinta
 
Phase III THEMIS
c.19,000 patients with T2D and CAD without a history of MI or stroke
Arm 1: Brilinta 60mg BID52
 
Arm 2: placebo BID on a background of aspirin if not contra-indicated53 or not tolerated
Composite of CV death, non-fatal MI and non-fatal stroke
FPCD
Q1 2014
 
LPCD
Q2 2016
Primary endpoint met
Phase III
THALES
c.11,000 patients with acute ischaemic stroke or transient ischaemic attack
Arm 1: Brilinta 90mg BID
 
Arm 2: placebo BID on a background of aspirin if not contra-indicated or not tolerated
Prevention of the composite of subsequent stroke and death at 30 days
FPCD
Q1 2018
 
LPCD
Q4 2019
Primary endpoint met
 
Fast Track
designation
(US)
 
c) 
Roxadustat (anaemia)
Roxadustat is currently undergoing US FDA review, with an anticipated regulatory decision expected at the end of this year. During the period, the US Institute for Clinical and Economic Review (ICER), an independent non-profit research institute that produces reports analysing the evidence on the effectiveness and value of medicines and other medical services, announced that it will assess the comparative clinical effectiveness and value of roxadustat for treatment of anaemia in CKD. The assessment is anticipated to be publicly discussed during a meeting of the California Technology Assessment Forum in February 2021, where the independent evidence review panel will deliberate and vote on evidence presented in ICER’s report.
 
In June 2020, FibroGen and Astellas presented data at the ERA-EDTA Virtual Congress from the Phase III DOLOMITES trial, which evaluated the efficacy and safety of roxadustat compared to darbepoetin alfa for the treatment of anaemia in NDD patients with Stage 3-5 CKD. In the primary endpoint analysis, the trial demonstrated non-inferiority of roxadustat compared to darbepoetin alfa in the proportion of patients achieving correction of haemoglobin (Hb) levels during the first 24 weeks of treatment (89.5% vs 78.0%; a difference of 11.51% [95% CI 5.66%-17.36%]), with a lower bound of 95% CI >0%. The response in correction of haemoglobin levels was defined as achieving Hb ≥11g/dL and Hb increase from baseline of ≥1g/dL with baseline Hb >8g/dL, or Hb increase from baseline of ≥2.0 g/dL in patients with baseline Hb ≤8.0 g/dL.
 
FibroGen and AstraZeneca have made a number of regulatory submissions in RoW countries, including Australia, Brazil, Canada, Chile, India, Mexico, Philippines, Singapore, South Korea, Taiwan. FibroGen and Astellas have received a regulatory approval in DD, and a regulatory submission acceptance for NDD in Japan, while in Europe, the FibroGen and Astellas received a regulatory submission acceptance from the EMA in May 2020.
 
Respiratory & Immunology
 
a) 
Bevespi (COPD)
In May 2020, Bevespi was approved in China as a maintenance treatment to relieve symptoms in patients with COPD, including chronic bronchitis and/or emphysema. The approval by the NMPA was based on positive results from the Phase III PINNACLE 4 trial in which Bevespi demonstrated a statistically significant improvement in lung function as measured by trough forced expiratory volume in one second, compared to its monotherapy components and placebo, all administered twice daily via pressurised metered-dose inhaler in patients with moderate to very severe COPD. The trial formed part of the broader PINNACLE clinical trials programme showing efficacy and safety and involving more than 5,000 patients across Asia, Europe and the US.
 
b) 
Breztri (COPD)
In July 2020, AstraZeneca announced that the US FDA had approved triple-combination therapy Breztri for the maintenance treatment of patients with COPD. The approval was based on positive results from the Phase III KRONOS and ETHOS trials.
 
During the period, results from the positive Phase III ETHOS trial showed that Breztri demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations, compared with two dual-combination therapies, in patients with moderate to very severe COPD. Compared with Bevespi, Breztri achieved a 24% reduction (p<0.001) in exacerbations; it also achieved a 13% reduction (p=0.003) compared with PT009. The dual-combination therapies used as comparators in the trial represented recommended therapeutic classes for the treatment of COPD. In a key secondary endpoint, Breztri showed a 46% reduction in the risk of all-cause mortality compared with Bevespi (95% CI 13%-66%).
 
The results were recently published in The New England Journal of Medicine and simultaneously presented at the American Thoracic Society Virtual Scientific Symposium. AstraZeneca will continue to review these data with health authorities.
 
c) 
PT027 (asthma)
PT027 is a potential first-in-class fixed-dose combination of budesonide, an ICS, and albuterol, a short-acting beta2 agonist. The Phase III programme is evaluating its use in all severities of asthma from four years of age as a rescue treatment. During the period, as a result of the COVID-19 pandemic, enrolment of new patients into the Phase III clinical development programme was paused in collaboration with co-development partner, Avillion LLP. Recruitment has since restarted, and data readouts are now anticipated in 2021.
 
d) 
Fasenra (eosinophil-driven diseases)
Table 32: Key Fasenra lifecycle management trials
 
Trial
Population
Design
Primary endpoint(s)
Timeline
Status
Phase III OSTRO
Patients (aged 18-75 years) with severe bilateral nasal polyposis; symptomatic, despite SoC
Placebo or Fasenra 30mg Q8W54 SC55
Nasal-polyposis burden and reported nasal blockage
FPCD
Q1 2018
 
LPCD
Q2 2019
 
Data anticipated
H2 2020
Recruitment completed
Phase III RESOLUTE
Patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils
Placebo or Fasenra 100mg Q8W SC
Annualised rate of moderate or severe COPD exacerbations
FPCD
Q4 2019
 
Data anticipated 2021+
Recruitment ongoing
Phase III
MANDARA
Eosinophilic granulomatosis with polyangiitis56
Fasenra 30mg or
mepolizumab 3x100mg Q4W57
Proportion of patients who achieve remission, defined as a score58 =0 and an OCS dose ≤4 mg/day at weeks 36 and 48
FPCD
Q4 2019
 
Data anticipated
2021+
Recruitment ongoing
 
Orphan Drug Designation (US)
Phase III
NATRON
HES59
Placebo or Fasenra 30mg Q4W SC
Time to HES worsening flare or any cytotoxic and/or immuno-suppressive therapy increase or hospitalisation
FPCD
Q3 2020
 
Data anticipated 2021+
Recruitment ongoing
 
Orphan Drug Designation (US)
Phase III
MESSINA
Eosinophilic oesophagitis60
Placebo or Fasenra 30mg Q4W SC
Proportion of patients with a histologic response
 
Changes from baseline in dysphagia PRO61
Data anticipated 2021+
Initiating
 
Orphan Drug Designation (US)
Phase III
FJORD
BP
Placebo or Fasenra 30mg Q4W SC
Proportion of patients with partial or
complete remission of BP whilst off OCS for ≥2 months
at Week 36
Data anticipated 2021+
Initiating
 
d) 
Tezepelumab (severe asthma)
During the period, Amgen Inc (Amgen) and AstraZeneca updated the 2012 collaboration agreement for tezepelumab. Under the amended agreement in the US, Amgen and AstraZeneca will jointly commercialise tezepelumab and Amgen will record sales in the US. AstraZeneca’s share of gross profits from tezepelumab in the US will be recognised as Collaboration Revenue. In Canada, Amgen and AstraZeneca will also jointly commercialise tezepelumab. In all territories outside the US and Canada, AstraZeneca will solely commercialise tezepelumab. AstraZeneca will record all sales outside of the US as Product Sales.
 
Other terms of clinical development and manufacturing remain unchanged. AstraZeneca continues to lead clinical development and Amgen continues to lead manufacturing. All aspects of the programme are under the oversight of joint governing bodies. Both companies will continue to share costs and profits equally after payment by AstraZeneca of a mid-single-digit royalty to Amgen. No payments are due to Amgen with regard to changes to the agreement.
 
e) 
Brazikumab (inflammatory bowel disease)
In May 2020, AstraZeneca completed a previously communicated agreement to recover the global rights to brazikumab (formerly MEDI2070), a monoclonal antibody targeting Interleukin-23. AstraZeneca and Allergan have terminated their previous licence agreement and all rights to brazikumab have therefore now returned to the Company.
 
COVID-19
 
a) 
AZD1222 (SARS-CoV-2 vaccine)
During the period, AstraZeneca advanced its ongoing response to address COVID-19 including licence, development and distribution agreements with the University of Oxford for the recombinant adenovirus vaccine, AZD1222.
 
The Phase I/II COV001 trial, launched in April 2020 in the UK with more than 1,000 participants, is ongoing. Initial data was reviewed in May 2020 by a Data Safety Monitoring Board and the UK Medicines and Healthcare products Regulatory Agency, resulting in the advancement to the COV002 Phase II/III trial in the UK, with over 10,000 participants.
 
In July 2020, results from the COV001 trial were published in The Lancet, showing that AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in evaluated participants. Neutralising activity against SARS-CoV-2 (as assessed by the MNA80 assay) was seen in 91% of participants (32/35) one month after vaccination and in 100% (10/10) of participants who received a second dose. In all evaluated participants, a T-cell response was induced, peaking by day 14, and maintained two months after injection. The levels of neutralising antibodies seen in participants receiving either one or two doses were in a similar range to those seen in convalescent COVID-19 patients. Data from these assays correlated positively with antibody levels to the SARS-CoV-2 spike protein, as measured by Enzyme-Linked Immunosorbent Assays data on the other participants.
 
COV002 has launched and has recruited almost 9,000 participants in the UK; late-stage development has begun in Brazil and South Africa. As part of the announced agreement with BARDA, the Company anticipates the launch of a Phase III clinical trial with c.30,000 participants in the US in the third quarter of this year.
 
b) 
AZD7442 (neutralising-antibody therapy for the prevention and treatment of COVID-19)
The Company’s comprehensive pandemic response includes rapid mobilisation of AstraZeneca’s global research efforts to discover novel coronavirus-neutralising antibodies to prevent and treat progression of the COVID-19 disease. During the period, AstraZeneca announced it had licensed coronavirus-neutralising antibodies from Vanderbilt University, US, and plans to advance two of these monoclonal antibodies (AZD8895 and AZD1061) into clinical development as a potential combination therapy (AZD7442) for the prevention and treatment of COVID-19. AstraZeneca has secured support from the Defense Advanced Research Projects Agency, part of the US Department of Defense and BARDA for the Phase I trial and the manufacturing of the potential new medicine for testing in Phase I, which is expected to initiate in the second half of the year.
 
In July 2020, the UK Government announced an agreement in principle with AstraZeneca for the supply of one million doses of AZD7442, with deliveries anticipated to start as early as first half of 2021, should the monoclonal-antibody combination prove to be tolerated and effective in clinical trials.
 
c) 
New and existing medicines in the treatment of COVID-19
As well as developing preventative approaches against the SARS-CoV-2 virus the Company also initiated clinical trials, detailed in the table below, to investigate AstraZeneca’s new and existing medicines to treat the infection by suppressing the body’s overactive immune response or protecting from serious complications, such as organ failure.
 
The Company is continuing to evaluate the use of Calquence, approved in a number of countries for the treatment of CLL, in the CALAVI Phase II trial, which is assessing the suppression of the cytokine storm that inflames the lungs and other organs of some COVID-19 patients. AstraZeneca is also looking at protecting organs in the Phase II DARE-19 trial, assessing whether Farxiga can potentially reduce organ failure. Farxiga is being evaluated in combination with ambrisentan in the Cambridge University Hospitals NHS Trust’s TACTIC-E trial. Farxiga is an oral SGLT2 inhibitor that has demonstrated benefits in heart failure and kidney disease.
 
The Company has joined the UK Government’s ACCORD proof-of-concept clinical-trial platform, to speed the development of medicines for patients with COVID-19 and is supplying Pulmicort and Symbicort to externally sponsored research programmes including the trials detailed below.
 
Table 33: Key trials in COVID-1962
 
Trial
Population
Design
Timeline
Status
AZD1222
Phase I/II
COV00163
(UK)
Protection against COVID-19 in participants aged 18-55
Control or
AZD1222
n=1,077
FPCD
Q2 2020
 
LPCD
Q2 2020
Initial data read out
Phase II/III
COV00269
(UK)
Protection against COVID-19 in participants aged 18-55, 55+ and paediatric
Control or
AZD1222
n=10,260
FPCD
Q2 2020
 
First data anticipated
H2 2020
Recruitment
ongoing
Phase III
D8110C00001
(US)
Protection against COVID-19 in participants aged 18+
Placebo or AZD1222
n=30,000
First data anticipated
H2 2020
Initiating
Phase I/IIChAdOx1 nCoV-19 ZA64
(South Africa)
Protection against COVID-19 in participants aged 18-65
HIV+65 subgroup
Placebo or AZD1222
n=2,200
FPCD
Q2 2020
 
First data anticipated
H2 2020
Recruitment
ongoing
Phase II/III
COV00366
(Brazil)
Protection against COVID-19 in participants aged 18-55
Control or
AZD1222
n>=5,000
FPCD
Q2 2020
 
First data anticipated
H2 2020
Recruitment ongoing
AZD7442
Phase I
COVID-19
Placebo or AZD7442
-
Initiating
Calquence
Phase II
CALAVI
(US and ex-US)
COVID-19
Current SoC or SoC+ Calquence
First data anticipated
H2 2020
Recruitment ongoing
Phase II
ACCORD67
COVID-19
Current SoC or current SoC + Calquence
First data anticipated
H2 2020
Recruitment ongoing
Farxiga
Phase II
DARE-19
COVID-19
Current SoC or current SoC +
Farxiga
First data anticipated
H2 2020
Recruitment ongoing
Phase II
TACTIC-E68
COVID-19
Current SoC or current SoC + Farxiga + ambrisentan
First data anticipated
H2 2020
Recruitment ongoing
MEDI3506
Phase II
ACCORD69
COVID-19
Current SoC or current SoC + MEDI3506
First data anticipated
H2 2020
Recruitment ongoing
Pulmicort
Phase IIIa
TACTIC-COVID70
COVID-19
Current SoC or SoC + Pulmicort
First data anticipated
H2 2020
Recruitment ongoing
Phase IIIa
STOIC71
COVID-19
Current SoC or SoC + Pulmicort
First data anticipated
H2 2020
Recruitment ongoing
Symbicort
Phase IIIa
INHASCO72
COVID-19
Current SoC or SoC + Symbicort
First data anticipated
H2 2020
Recruitment ongoing
 
 

For more details on the development pipeline, including anticipated timelines for regulatory submission/acceptances, please refer to the latest Clinical Trials Appendix available on astrazeneca.com.
 

 
 
Interim Financial Statements
 
Table 34: Condensed consolidated statement of comprehensive income - H1 2020
 
For the half year ended 30 June
2020
2019
$m
$m
Total Revenue
12,629
11,314
Product Sales
12,359
11,183
Collaboration Revenue
270
131
 
 
 
Cost of Sales
(2,404)
(2,192)
 
 
 
Gross Profit
10,225
9,122
 
 
 
Distribution costs
(191)
(159)
Research and development expense
(2,777)
(2,622)
Selling, general and administrative costs
(5,354)
(5,457)
Other operating income and expense
601
706
 
 
 
Operating Profit
2,504
1,590
Finance income
73
96
Finance expense
(661)
(728)
Share of after-tax losses in associates and joint ventures
(20)
(59)
 
 
 
Profit Before Tax
1,896
899
Taxation
(408)
(229)
Profit for the period
1,488
670
 
 
 
Other comprehensive income
 
 
Items that will not be reclassified to profit or loss
 
 
Remeasurement of the defined benefit pension liability
(205)
(247)
Net gains/(losses) on equity investments measured at fair value through other comprehensive income
1,069
(54)
Fair value movements related to own credit risk on bonds designated as fair value through profit or loss
6
(2)
Tax on items that will not be reclassified to profit or loss
(79)
17
 
791
(286)
Items that may be reclassified subsequently to profit or loss
 
 
Foreign exchange arising on consolidation
(494)
(86)
Foreign exchange arising on designating borrowings in net investment hedges
(17)
(186)
Fair value movements on cash flow hedges
(131)
(43)
Fair value movements on cash flow hedges transferred to profit or loss
(1)
14
Fair value movements on derivatives designated in net investment hedges
60
(9)
Costs of hedging
4
3
Tax on items that may be reclassified subsequently to profit or loss
29
20
 
(550)
(287)
Other comprehensive income/(loss) for the period, net of tax
241
(573)
Total comprehensive income for the period
1,729
97
 
 
 
Profit attributable to:
 
 
Owners of the Parent
1,536
723
Non-controlling interests
(48)
(53)
 
1,488
670
Total comprehensive income attributable to:
 
 
Owners of the Parent
1,777
150
Non-controlling interests
(48)
(53)
 
1,729
97
Basic earnings per $0.25 Ordinary Share
$1.17
$0.56
Diluted earnings per $0.25 Ordinary Share
$1.17
$0.56
 
 
 
Weighted average number of Ordinary Shares in issue (millions)
1,312
1,289
Diluted weighted average number of Ordinary Shares in issue (millions)
1,313
1,290
 
Table 35: Condensed consolidated statement of comprehensive income - Q2 2020
 
For the quarter ended 30 June
Unreviewed732020
Unreviewed2019
$m
$m
Total Revenue
6,275
5,823
Product Sales
6,048
5,718
Collaboration Revenue
227
105
Cost of Sales
(984)
(1,063)
Gross Profit
5,291
4,760
 
 
 
Distribution costs
(104)
(81)
Research and development expense
(1,389)
(1,356)
Selling, general and administrative costs
(2,635)
(2,943)
Other operating income and expense
121
113
 
 
 
Operating Profit
1,284
493
Finance income
22
41
Finance expense
(329)
(361)
Share of after-tax losses in associates and joint ventures
(16)
(32)
 
 
 
Profit Before Tax
961
141
Taxation
(223)
(34)
Profit for the period
738
107
 
 
 
Other comprehensive income
 
 
Items that will not be reclassified to profit or loss
 
 
Remeasurement of the defined benefit pension liability
(645)
(257)
Net gains/(losses) on equity investments measured at fair value through other comprehensive income
898
(174)
Fair value movements related to own credit risk on bonds designated as fair value through profit or loss
(15)
(1)
Tax on items that will not be reclassified to profit or loss
(13)
60
 
225
(372)
Items that may be reclassified subsequently to profit or loss
 
 
Foreign exchange arising on consolidation
114
(139)
Foreign exchange arising on designating borrowings in net investment hedges
363
(6)
Fair value movements on cash flow hedges
56
11
Fair value movements on cash flow hedges transferred to profit or loss
(46)
(33)
Fair value movements on derivatives designated in net investment hedges
-
(12)
Costs of hedging
9
9
Tax on items that may be reclassified subsequently to profit or loss
(44)
(3)
 
452
(173)
Other comprehensive income/(loss) for the period, net of tax
677
(545)
Total comprehensive income/(loss) for the period
1,415
(438)
 
 
 
Profit attributable to:
 
 
Owners of the Parent
756
130
Non-controlling interests
(18)
(23)
 
738
107
Total comprehensive income attributable to:
 
 
Owners of the Parent
1,432
(415)
Non-controlling interests
(17)
(23)
 
1,415
(438)
Basic earnings per $0.25 Ordinary Share
$0.58
$0.09
Diluted earnings per $0.25 Ordinary Share
$0.58
$0.10
 
 
 
Weighted average number of Ordinary Shares in issue (millions)
1,312
1,311
Diluted weighted average number of Ordinary Shares in issue (millions)
1,313
1,312
 
Table 36: Condensed consolidated statement of financial position
 
At 30 Jun 2020
At 31 Dec 2019
At 30 Jun 2019
$m
$m
$m
Assets
 
 
 
Non-current assets
 
 
 
Property, plant and equipment
7,475
7,688
7,442
Right-of-use assets
634
647
702
Goodwill
11,645
11,668
11,668
Intangible assets
19,728
20,833
22,257
Investments in associates and joint ventures
41
58
73
Other investments
1,577
1,401
1,362
Derivative financial instruments
122
61
124
Other receivables
644
740
454
Deferred tax assets
3,133
2,718
2,588
 
 
 
 
 
44,999
45,814
46,670
 
 
 
 
Current assets
 
 
 
Inventories
3,562
3,193
3,197
Trade and other receivables
5,024
5,761
5,319
Other investments
442
849
819
Derivative financial instruments
16
36
210
Income tax receivable
213
285
246
Cash and cash equivalents
5,673
5,369
5,428
Assets held for sale
-
70
-
 
14,930
15,563
15,219
 
 
 
 
Total assets
59,929
61,377
61,889
 
 
 
 
 
 
 
 
Liabilities
 
 
 
Current liabilities
 
 
 
Interest-bearing loans and borrowings
(3,958)
(1,822)
(1,629)
Lease liabilities
(174)
(188)
(206)
Trade and other payables
(12,028)
(13,987)
(12,637)
Derivative financial instruments
(35)
(36)
(11)
Provisions
(612)
(723)
(410)
Income tax payable
(1,376)
(1,361)
(1,141)
 
(18,183)
(18,117)
(16,034)
Non-current liabilities
 
 
 
Interest-bearing loans and borrowings
(15,150)
(15,730)
(17,355)
Lease liabilities
(465)
(487)
(514)
Derivative financial instruments
(121)
(18)
(2)
Deferred tax liabilities
(2,526)
(2,490)
(2,932)
Retirement benefit obligations
(2,847)
(2,807)
(2,632)
Provisions
(835)
(841)
(376)
Other payables
(6,144)
(6,291)
(6,973)
 
(28,088)
(28,664)
(30,784)
Total liabilities
(46,271)
(46,781)
(46,818)
 
 
 
 
Net assets
13,658
14,596
15,071
 
 
 
 
Equity
 
 
 
Capital and reserves attributable to equity holders of the Parent
 
 
 
Share capital
328
328
328
Share premium account
7,950
7,941
7,911
Other reserves
2,046
2,046
2,044
Retained earnings
1,913
2,812
3,265
 
 
 
 
 
12,237
13,127
13,548
 
 
 
 
Non-controlling interests
1,421
1,469
1,523
Total equity
13,658
14,596
15,071
 
Table 37: Condensed consolidated statement of changes in equity
 
 
Share capital
Share premium account
Other reserves
Retained earnings
Total attributable to owners of the parent
Non-controlling interests
Total equity
 
$m
$m
$m
$m
$m
$m
$m
At 1 Jan 2019
317
4,427
2,041
5,683
12,468
1,576
14,044
 
 
 
 
 
 
 
 
Adoption of new accounting standards
-
-
-
54
54
-
54
Profit for the period
-
-
-
723
723
(53)
670
Other comprehensive loss
-
-
-
(573)
(573)
-
(573)
Transfer to other reserves
-
-
3
(3)
-
-
-
Transactions with owners:
 
 
 
 
 
 
 
Dividends
-
-
-
(2,403)
(2,403)
-
(2,403)
Issue of Ordinary Shares
11
3,484
-
-
3,495
-
3,495
Share-based payments charge for the period
-
-
-
102
102
-
102
Settlement of share plan awards
-
-
-
(318)
(318)
-
(318)
 
 
 
 
 
 
 
 
Net movement
11
3,484
3
(2,418)
1,080
(53)
1,027
 
 
 
 
 
 
 
 
At 30 Jun 2019
328
7,911
2,044
3,265
13,548
1,523
15,071
 
 
 
 
 
 
 
 
At 1 Jan 2020
328
7,941
2,046
2,812
13,127
1,469
14,596
 
 
 
 
 
 
 
 
Profit for the period
-
-
-
1,536
1,536
(48)
1,488
Other comprehensive income
-
-
-
241
241
-
241
Transfer to other reserves
-
-
-
-
-
-
-
Transactions with owners:
 
 
 
 
 
 
-
Dividends
-
-
-
(2,489)
(2,489)
-
(2,489)
Issue of Ordinary Shares
-
9
-
-
9
-
9
Share-based payments charge for the period
-
-
-
118
118
-
118
Settlement of share plan awards
-
-
-
(305)
(305)
-
(305)
 
 
 
 
 
 
 
 
Net movement
-
9
-
(899)
(890)
(48)
(938)
 
 
 
 
 
 
 
 
At 30 Jun 2020
328
7,950
2,046
1,913
12,237
1,421
13,658
 
Table 38: Condensed consolidated statement of cash flows
 
For the half year ended 30 June
2020
2019
$m
$m
Cash flows from operating activities
 
 
Profit Before Tax
1,896
899
Finance income and expense
588
632
Share of after-tax losses of associates and joint ventures
20
59
Depreciation, amortisation and impairment
1,551
1,403
Increase in working capital and short-term provisions
(780)
(634)
Gains on disposal of intangible assets
(411)
(590)
Fair value movements on contingent consideration arising from business combinations
(44)
-
Non-cash and other movements
(511)
(177)
 
 
 
Cash generated from operations
2,309
1,592
Interest paid
(338)
(378)
Tax paid
(792)
(723)
 
 
 
Net cash inflow from operating activities
1,179
491
 
 
 
Cash flows from investing activities
 
 
Payment of contingent consideration from business combinations
(353)
(368)
Purchase of property, plant and equipment
(370)
(438)
Disposal of property, plant and equipment
67
27
Purchase of intangible assets
(983)
(1,296)
Disposal of intangible assets
474
1,071
Movement in profit-participation liability
-
150
Purchase of non-current asset investments
(119)
(7)
Disposal of non-current asset investments
949
18
Movement in short-term investments, fixed deposits and other investing instruments
463
21
Payments to associates and joint ventures
(8)
(39)
Interest received
37
72
 
 
 
Net cash inflow/(outflow) from investing activities
157
(789)
 
 
 
Net cash inflow/(outflow) before financing activities
1,336
(298)
 
 
 
Cash flows from financing activities
 
 
Proceeds from issue of share capital
9
3,495
Issue of loans
-
500
Repayment of loans
-
(500)
Dividends paid
(2,398)
(2,432)
Hedge contracts relating to dividend payments
(93)
26
Repayment of obligations under leases
(107)
(84)
Movement in short-term borrowings
1,353
(64)
 
 
 
Net cash (outflow)/inflow from financing activities
(1,236)
941
 
 
 
Net increase in cash and cash equivalents in the period
100
643
Cash and cash equivalents at the beginning of the period
5,223
4,671
Exchange rate effects
(18)
16
 
 
 
Cash and cash equivalents at the end of the period
5,305
5,330
 
 
 
Cash and cash equivalents consist of:
 
 
Cash and cash equivalents
5,673
5,428
Overdrafts
(368)
(98)
 
 
 
 
5,305
5,330
 
Responsibility statement of the directors in respect of the half-yearly financial report
 
We confirm that to the best of our knowledge:
 
-
the condensed consolidated Interim Financial Statements have been prepared in accordance with IAS 34 ‘Interim Financial Reporting’ as issued by the International Accounting Standards Board and adopted by the European Union;
 
-
the half-yearly management report includes a fair review of the information required by:
 
a)
DTR 4.2.7R of the Disclosure and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed consolidated Interim Financial Statements; and a description of the principal risks and uncertainties for the remaining six months of the year; and
 
b)
DTR 4.2.8R of the Disclosure and Transparency Rules, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the enterprise during that period; and any changes in the related party transactions described in the last annual report that could do so.
 
The Board
The Board of Directors that served during all or part of the six-month period to 30 June 2020 and their respective responsibilities can be found on the Leadership team section of astrazeneca.com.
 
Approved by the Board and signed on its behalf by
 
Pascal Soriot
Chief Executive Officer
 
30 July 2020
 
Independent review report to AstraZeneca PLC
 
Report on the condensed consolidated interim financial statements
 
Our conclusion
We have reviewed AstraZeneca PLC's condensed consolidated interim financial statements (the ‘Interim Financial Statements’) in the half-yearly financial report of AstraZeneca PLC for the 6-month period ended 30 June 2020. Based on our review, nothing has come to our attention that causes us to believe that the Interim Financial Statements are not prepared, in all material respects, in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’, as issued by the International Accounting Standards Board (IASB) and as adopted by the European Union and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority.
 
What we have reviewed
 
The Interim Financial Statements comprise:
 
-
the Condensed consolidated statement of financial position as at 30 June 2020;
 
-
the Condensed consolidated statement of comprehensive income – H1 2020 for the period then ended;
 
-
the Condensed consolidated statement of cash flows for the period then ended;
 
-
the Condensed consolidated statement of changes in equity for the period then ended; and
 
-
the explanatory notes to the Interim Financial Statements.
 
The Interim Financial Statements included in the half-yearly financial report have been prepared in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’, as issued by the IASB and as adopted by the European Union and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority.
 
As disclosed in note 1 to the Interim Financial Statements, the financial reporting framework that has been applied in the preparation of the full annual financial statements of the Group is applicable law and International Financial Reporting Standards as issued by the IASB and as adopted by the European Union.
 
Responsibilities for the interim financial statements and the review
 
Our responsibilities and those of the directors
The half-yearly financial report, including the Interim Financial Statements, is the responsibility of, and has been approved by, the directors. The directors are responsible for preparing the half-yearly financial report in accordance with the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority.
 
Our responsibility is to express a conclusion on the Interim Financial Statements in the half-yearly financial report based on our review. This report, including the conclusion, has been prepared for and only for the company for the purpose of complying with the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority and for no other purpose. We do not, in giving this conclusion, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.
 
What a review of interim financial statements involves
We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410, ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’ issued by the Auditing Practices Board for use in the United Kingdom. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures.
 
A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK) and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
 
We have read the other information contained in the half-yearly financial report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the Interim Financial Statements.
 
PricewaterhouseCoopers LLP
Chartered Accountants
London
30 July 2020
 
Notes to the Interim Financial Statements
 
1)
Basis of preparation and accounting policies
These unaudited Interim Financial Statements for the six months ended 30 June 2020 have been prepared in accordance with IAS 34 ‘Interim Financial Reporting’ as issued by the International Accounting Standards Board (IASB) and as adopted by the EU. The UK is in the process of establishing its post-Brexit IFRS-adoption authority, which is expected to be operational later in 2020, but for the current time, will follow the EU approval process.
 
The unaudited Interim Financial Statements for the six months ended 30 June 2020 were approved by the Board of Directors for release on 30 July 2020.
 
The annual financial statements of the Group are prepared in accordance with IFRSs as issued by the IASB and adopted by the EU. Except as noted below, the Interim Financial Statements have been prepared applying the accounting policies that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2019.
 
IFRS 3
An amendment to IFRS 3 ‘Business Combinations’ relating to the definition of a business was endorsed by the EU in April 2020 with an effective date of 1 January 2020. The change in definition of a business within IFRS 3 introduces an optional concentration test to perform a simplified assessment of whether an acquired set of activities and assets is or is not a business on a transaction by transaction basis. This change is expected to provide more reliable and comparable information about certain transactions as it provides more consistency in accounting in the pharmaceutical industry for substantially similar transactions for which, under the previous definition, may have been accounted in different ways, despite limited differences in substance. The Group has adopted this amendment from the effective date.
 
IFRS 9, IAS 39 and IFRS 7
Amendments to IFRS 9 ‘Financial Instruments’, IAS 39 ‘Financial Instruments: Recognition and Measurement’ and IFRS 7 ‘Financial Instruments: Disclosures’ relating to interbank offered rate (IBOR) reform were endorsed by the EU in January 2020. The Group adopted the amendments in the year ended 31 December 2019. The replacement of benchmark interest rates such as the London Inter-bank Offered Rate (LIBOR) and other IBORs is a priority for global regulators. The amendments provide relief from applying specific hedge-accounting requirements to hedge relationships directly affected by IBOR reform and have the effect that IBOR reform should generally not cause hedge accounting to terminate. There is no financial impact from the early adoption of these amendments.
 
The Group has one IFRS 9 designated hedge relationship that is potentially impacted by IBOR reform, namely a €300m cross-currency interest-rate swap in a fair-value hedge relationship with €300m of a €750m 0.875% 2021 non-callable bond. This swap references three-month USD LIBOR and uncertainty arising from the Group’s exposure to IBOR reform will cease when the swap matures in 2021. The implications on the wider business of IBOR reform are currently being assessed.
 
COVID-19
AstraZeneca has assessed the impact of the uncertainty presented by the COVID-19 pandemic on the Interim Financial Statements comprising the financial results to 30 June 2020 and the financial position as at 30 June 2020, specifically considering the impact on key judgements and significant estimates as detailed on page 173 of the Annual Report and 20-F Information 2019 along with a several other areas of increased risk.
 
A detailed assessment has been performed, focussing on the following areas:
 
-
recoverable value of goodwill, intangible assets and property, plant and equipment
 
-
impact on key assumptions used to estimate contingent-consideration liabilities
 
-
key assumptions used in estimating the Group’s defined-benefit pension obligations

-
basis for estimating clinical-trial accruals
 
-
key assumptions used in estimating rebates, chargebacks and returns for US Product Sales
 
-
valuations of unlisted equity investments
 
-
expected credit losses associated with changes in credit risk relating to trade and other receivables
 
-
net realisable value of inventories
 
-
fair value of certain financial instruments
 
-
recoverability of deferred-tax assets
 
-
effectiveness of hedge relationships
 
Given the significant volatility experienced in the financial markets, the assumptions used to estimate the Group’s material defined-benefit pension obligations are updated quarterly and resulted in an overall $40m increase in the Group’s defined-benefit pension deficit in the six months ended 30 June 2020. The increase in the deficit primarily reflected increased liability valuations as a result of lower discount rates (due to falling long term AA corporate bond yields linked to the launch of a quantitative easing bond-buying programme in the UK and other regions in June 2020), with an increase in asset values providing a partial offset. In the UK, £79m of deficit-recovery contributions were also paid during the period. The sensitivity of the Group’s main defined-benefit liability valuations to changes in assumptions is set out on page 207 of the Annual Report and Form 20-F Information 2019.
 
No further material accounting impacts relating to the areas assessed above were recognised during the six-month period ending 30 June 2020.
 
The Group will continue to monitor these areas of increased judgement, estimation and risk for material changes.
 
Going concern
The Group has considerable financial resources available. As at 30 June 2020, the Group had $10.2bn in financial resources (cash and cash-equivalent balances of $5.7bn, $0.4bn of liquid fixed income securities and undrawn committed bank facilities of $4.1bn, of which $3.4bn is available until April 2022, $0.5bn is available until November 2020 (extendable to November 2021) and $0.2bn is available until December 2020, with only $4.1bn of borrowings due within one year). The Group’s revenues are largely derived from sales of medicines that are covered by patents which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to affect adversely revenues in many of the mature markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. In the current environment, the Directors have also considered the impact of possible future COVID-19 related scenarios and believe the Group retains sufficient liquidity to continue to operate.
 
Based on the above paragraph, the going-concern basis has been adopted in these Interim Financial Statements.
 
Legal proceedings
The information contained in Note 5 updates the disclosures concerning legal proceedings and contingent liabilities in the Group’s Annual Report and Form 20-F Information 2019.
 
Financial information
The comparative figures for the financial year ended 31 December 2019 are not the Group’s statutory accounts for that financial year. Those accounts have been reported on by the Group’s auditors and have been delivered to the registrar of companies; their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006.
 
2)
Intangible assets
In accordance with IAS 36 ‘Impairment of Assets’, reviews for triggers at an individual asset or cash-generating-unit level were conducted. This resulted in a total impairment charge of $119m being recorded against intangible assets during the six months ended 30 June 2020.
 
During the first quarter of 2020, a charge of $102m was recorded in relation to Bydureon (revised carrying amount of $612m). The impairment was driven by an overall reduction in forecast Total Revenue over the remaining asset life, reflecting expectations of returns from promotional activities, including a level of anticipated impact resulting from the restrictions in place due to the COVID-19 pandemic. If Total Revenue projections for Bydureon were to decline by a further 10% over the forecast period, it would result in a reduction in the recoverable amount of c.$100m.
 
During the second quarter, charges recorded included $65m and $31m in relation to Duaklir and Eklira/Tudorza, respectively, (revised carrying amount of $274m and $130m, respectively), and a $95m impairment reversal in relation to FluMist (revised carrying amount of $258m).
 
The impairment charges for Duaklir and Eklira/Tudorza were a consequence of revised market volume and share assumptions following adverse performances during H1 2020, compared to previous forecasts during the H1 2020. If Total Revenue projections for these assets were to decline by a further 20% over the forecast period, it would result in additional reductions to the recoverable amounts of c.$60m for Duaklir and c.$30m for Eklira/Tudorza.
 
The $95m impairment reversal in relation to FluMist reflected a change in expected sales volumes, following pre-orders received during the period.
 
3)
Net Debt
The table below provides an analysis of Net Debt and a reconciliation of Net Cash Flow to the movement in Net Debt. The Group monitors Net Debt as part of its capital-management policy as described in Note 27 of the Annual Report and Form 20-F Information 2019. Net Debt is a non-GAAP financial measure.
 
Table 39: Net Debt
 
At
1 Jan 2020
Cash flow
Non-cash & other
Exchange movements
At
30 Jun 2020
$m
$m
$m
$m
$m
Non-current instalments of loans
(15,730)
-
550
30
(15,150)
Non-current instalments of leases
(487)
-
11
11
(465)
 
 
 
 
 
 
Total long-term debt
(16,217)
-
561
41
(15,615)
 
 
 
 
 
 
Current instalments of loans
(1,597)
-
(556)
(6)
(2,159)
Current instalments of leases
(188)
117
(107)
4
(174)
Commercial paper
-
(1,262)
-
-
(1,262)
Bank collateral
(71)
(34)
-
-
(105)
Other short-term borrowings excluding overdrafts
(8)
(57)
-
1
(64)
Overdraft
(146)
(230)
-
8
(368)
 
 
 
 
 
 
Total current debt
(2,010)
(1,466)
(663)
7
(4,132)
 
 
 
 
 
 
Gross borrowings
(18,227)
(1,466)
(102)
48
(19,747)
 
 
 
 
 
 
Net derivative financial instruments
43
93
(154)
-
(18)
 
 
 
 
 
 
Net borrowings
(18,184)
(1,373)
(256)
48
(19,765)
 
 
 
 
 
 
Cash and cash equivalents
5,369
330
-
(26)
5,673
Other investments - current
849
(463)
62
(6)
442
Other investments - non-current
62
-
(62)
-
-
Cash and investments
6,280
(133)
-
(32)
6,115
 
 
 
 
 
 
Net Debt
(11,904)
(1,506)
(256)
16
(13,650)
 
Non-cash movements in the period include fair-value adjustments under IFRS 9.
 
Other investments - non-current are included within the balance of $1,577m (31 December 2019: $1,401m) in the Condensed consolidated statement of financial position. The equivalent GAAP measure to net debt is ‘liabilities arising from financing activities’ which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives shown above and includes the Acerta Pharma put-option liability of $2,219m (31 December 2019: $2,146m) shown in non-current other payables.
 
Net Debt increased by $1,746m in the six months to 30 June 2020, principally due to Net Cash Inflow from Operating Activities of $1,179m being more than offset by the payment of the second interim dividend of 2019 of $2,398m (representing two thirds of the 2019 full year).
 
Details of the committed undrawn bank facilities are disclosed within the going-concern section of Note 1.
 
During the six months to 30 June 2020, there were no changes to the Company’s credit ratings issued by Standard and Poor’s (long term: BBB+, short term A-2) and Moody’s (long term: A3, short term P-2).
 
4)
Financial instruments
As detailed in the Group’s most recent annual financial statements, the principal financial instruments consist of derivative financial instruments, other investments, trade and other receivables, cash and cash equivalents, trade and other payables, leases and interest-bearing loans and borrowings. During the period, equity investments previously categorised as Level 3 in the fair-value hierarchy (carrying value of $103m at 31 December 2019) are now categorised as Level 1 (carrying value of $188m at 30 June 2020) on availability of quoted prices in an active market. There have been no other changes of significance to the categorisation or fair-value hierarchy classification of financial instruments from those detailed in the Notes to the Group Financial Statements in the Annual Report and Form 20-F Information 2019.
 
The Group holds certain equity investments that are categorised as Level 3 in the fair-value hierarchy and for which fair-value gains of $65m have been recognised in the six months ended 30 June 2020. All other fair-value gains and/or losses that are presented in Net gains/(losses) on Equity Investments measured at fair value through other comprehensive income in the condensed consolidated statement of comprehensive income for the six months ended 30 June 2020 are Level 1 fair value measurements.
 
Financial instruments measured at fair value include $2,019m of other investments, $4,743m held in money-market funds, $339m of loans designated at fair value through profit or loss, $339m of loans designated in a fair-value hedge relationship and ($18m) of derivatives as at 30 June 2020. The total fair value of interest-bearing loans and borrowings at 30 June 2020, which have a carrying value of $19,747m in the Condensed consolidated statement of financial position, was $22,992m. Contingent-consideration liabilities arising on business combinations have been classified under Level 3 in the fair-value hierarchy and movements in fair value are shown below:
 
Table 40: Financial instruments
 
2020
2019
Diabetes alliance
Other
Total
Total
$m
$m
$m
$m
At 1 January
3,300
839
4,139
5,106
Settlements
(257)
(96)
(353)
(368)
Revaluations
(22)
(22)
(44)
-
Discount unwind
115
26
141
179
 
 
 
 
 
At 30 June
3,136
747
3,883
4,917
 
Contingent consideration arising from business combinations is fair-valued using decision-tree analysis, with key inputs including the probability of success, consideration of potential delays and the expected levels of future revenues.
 
The contingent consideration balance relating to BMS’s share of the global diabetes alliance of $3,136m (31 December 2019: $3,300m) would increase/decline by $314m with an increase/decline in sales of 10%, as compared with the current estimates.
 
Included within the BMS contingent consideration liability are estimates of royalties payable in relation to Bydureon. The revised Total Revenue projections for Bydureon also resulted in a $22m reduction in the contingent consideration balance as at 30 June 2020. A further 10% reduction in Bydureon Total Revenue would result in an additional $22m reduction.
 
5)
Legal proceedings and contingent liabilities
AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and investigations relating to product liability, commercial disputes, infringement of intellectual property rights, the validity of certain patents, anti-trust law and sales and marketing practices. The matters discussed below constitute the more significant developments since publication of the disclosures concerning legal proceedings in the Company's Annual Report and Form 20-F Information 2019 (the Disclosures). Unless noted otherwise below or in the Disclosures, no provisions have been established in respect of the claims discussed below.
As discussed in the Disclosures, for the majority of claims in which AstraZeneca is involved, it is not possible to make a reasonable estimate of the expected financial effect, if any, that will result from ultimate resolution of the proceedings. In these cases, AstraZeneca discloses information with respect only to the nature and facts of the cases, but no provision is made.
 
In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed and which are not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate of the loss, AstraZeneca records the loss absorbed or makes a provision for its best estimate of the expected loss. The position could change over time and the estimates that the Company made, and upon which the Company has relied in calculating these provisions are inherently imprecise. There can, therefore, be no assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of the provisions that have been booked in the accounts. The major factors causing this uncertainty are described more fully in the Disclosures and herein.
 
AstraZeneca has full confidence in, and will vigorously defend and enforce, its intellectual property.
 
Matters disclosed in respect of the second quarter of 2020 and to 30 July 2020
 
Patent litigation
 
Tagrisso
US patent proceedings
As previously disclosed, in February 2020, in response to Paragraph IV notices from multiple abbreviated new drug application (ANDA) filers, AstraZeneca filed patent infringement lawsuits in the US District Court for the District of Delaware. In its complaint, AstraZeneca alleged that a generic version of Tagrisso, if approved and marketed, would infringe a US Orange Book-listed Tagrisso patent. The trial is scheduled for May 2022.
 
Faslodex
Patent proceedings outside the US
In Italy, Actavis Group Ptc ehf and Actavis Italy S.p.A. filed actions alleging that the Italian part of European Patent No. EP 1,250,138 (the ‘138 patent) and European Patent Nos. EP 2,266,573 (the ‘573 patent) are invalid. In July 2018, the Court of Turin determined that the ‘138 patent is invalid. In July 2019, the Court of Milan determined that the ‘573 patent is invalid. AstraZeneca appealed both decisions. In June 2020, the Court of Appeal of Turin upheld the invalidity decision as to the ‘138 patent. Patent infringement and patent-invalidity proceedings are ongoing against various parties.
 
In Russia, in July 2020, following a challenge to the validity of the Faslodex formulation patent by ZAO BIOCAD (Biocad), the Russian Patent Office maintained the patent as valid and dismissed the opposition filed by Biocad.
 
Symbicort
US patent proceedings
As previously disclosed, AstraZeneca has ANDA litigation against Mylan Pharmaceuticals Inc. (Mylan) and 3M Company (3M) in the US District Court for the Northern District of West Virginia. In the action, AstraZeneca alleges that the defendants’ generic versions of Symbicort, if approved and marketed, would infringe various AstraZeneca patents. Mylan and 3M allege that their proposed generic product does not infringe the asserted patents and/or that the asserted patents are invalid and/or unenforceable. In July 2020, AstraZeneca added Kindeva Drug Delivery L.P. as a defendant in the case. The trial of the matter is scheduled for October 2020.
 
Product liability litigation
 
Nexium and Losec/Prilosec
As previously disclosed, in the US, AstraZeneca is defending various lawsuits brought in federal and state courts involving multiple plaintiffs claiming that they have been diagnosed with various injuries following treatment with proton pump inhibitors (PPIs), including Nexium and Prilosec. The vast majority of those lawsuits relate to allegations of kidney injuries. In particular, in May 2017, counsel for a group of such plaintiffs claiming that they have been diagnosed with kidney injuries filed a motion with the Judicial Panel on Multidistrict Litigation (JPML) seeking the transfer of any currently pending federal court cases as well as any similar, subsequently filed cases to a coordinated and consolidated pre-trial multidistrict litigation (MDL) proceeding. In August 2017, the JPML granted the motion and consolidated the pending federal court cases in an MDL proceeding in federal court in New Jersey for pre-trial purposes. A trial in the MDL has been scheduled for November 2021. In addition to the MDL cases, there are cases filed in several state courts around the US.
 
In addition, AstraZeneca has been defending lawsuits involving allegations of gastric cancer following treatment with PPIs. All but one of these claims is filed in the MDL. One claim is filed in the US District Court for the Middle District of Louisiana, where the court has scheduled a trial for March 2022.
 
Commercial litigation
 
Amplimmune
As previously disclosed, in June 2017, AstraZeneca was served with a lawsuit filed by the stockholders' agents for Amplimmune, Inc. (Amplimmune) in Delaware State Court that alleged, among other things, breaches of contractual obligations relating to a 2013 merger agreement between AstraZeneca and Amplimmune. Trial of the matter was held in February 2020 and post-trial oral argument is scheduled for August 2020.
 
Array
In December 2017, AstraZeneca was served with a complaint filed in New York State court by Array BioPharma, Inc. (Array) alleging breaches of contractual obligations relating to a 2003 collaboration agreement between AstraZeneca and Array. In June 2020, an appeal court denied AstraZeneca’s motion for an early dismissal of the case, allowing the case to continue towards trial. No trial date has been set.
 
Anti-Terrorism Act Civil Lawsuit
As previously disclosed, in October 2017, AstraZeneca and certain other pharmaceutical and/or medical device companies were named as defendants in a complaint, filed in the US District Court for the District of Columbia (the District Court) by US nationals (or their estates, survivors, or heirs) who were killed or wounded in Iraq between 2005 and 2011, that alleged that the defendants violated the US Anti-Terrorism Act and various state laws by selling pharmaceuticals and medical supplies to the Iraqi Ministry of Health. In July 2020, the District Court granted AstraZeneca’s and its co-defendants’ jointly filed motion and dismissed the lawsuit in its entirety.
 
Ocimum lawsuit
In December 2017, AstraZeneca was served with a complaint filed by Ocimum Biosciences, Ltd. (Ocimum) in the Superior Court for the State of Delaware that alleges, among other things, breaches of contractual obligations and misappropriation of trade secrets, relating to a now terminated 2001 licensing agreement between AstraZeneca and Gene Logic, Inc. (Gene Logic), the rights to which Ocimum purports to have acquired from Gene Logic. In December 2019, the court granted AstraZeneca’s motion for summary judgment and dismissed the case. Ocimum has appealed.
 
Government investigations/proceedings
 
Synagis
Litigation in New York
As previously disclosed, in the US, in June 2011, MedImmune received a demand from the US Attorney’s Office for the Southern District of New York requesting certain documents related to the sales and marketing activities of Synagis. In July 2011, MedImmune received a similar court order to produce documents from the Office of the Attorney General for the State of New York Medicaid and Fraud Control Unit pursuant to what the government attorneys advised was a joint investigation. MedImmune has cooperated with these inquiries.
 
In March 2017, MedImmune was served with a lawsuit filed in US District Court for the Southern District of New York by the Attorney General for the State of New York alleging that MedImmune inappropriately provided assistance to a single specialty care pharmacy. In September 2018, the US District Court in New York denied MedImmune’s motion to dismiss the lawsuit brought by the Attorney General for the State of New York. This matter has been resolved and is now concluded.
 
In June 2017, MedImmune was served with a lawsuit in US District Court for the Southern District of New York by a relator under the qui tam (whistleblower) provisions of the federal and certain state False Claims Acts. The lawsuit was originally filed under seal in April 2009 and alleges that MedImmune made false claims about Synagis. In November 2017, MedImmune was served with an amended complaint in which relator set forth additional false claims allegations relating to Synagis. In September 2018, the US District Court in New York dismissed the relator’s lawsuit. In January 2019, relator appealed the decision of the US District Court in New York. In March 2020, the United States Court of Appeals for the Second Circuit affirmed the US District Court’s decision dismissing the relator’s lawsuit. This matter is now concluded.
 
Toprol-XL
Louisiana Attorney General Litigation
As previously disclosed, in April 2019, a Louisiana state court (State Court) granted AstraZeneca’s motion for summary judgment and dismissed a state court complaint brought by the Attorney General for the State of Louisiana (the State), which alleged that, in connection with enforcement of its patents for Toprol-XL, AstraZeneca engaged in unlawful monopolisation and unfair trade practices, causing the State government to pay increased prices for Toprol-XL, and the State appealed that ruling. In July 2020, the Louisiana First Court of Appeals reversed the State Court’s ruling and remanded the case to the State Court.
 
Matters disclosed in respect of the first quarter of 2020 and to 29 April 2020
 
Patent litigation
 
Tagrisso
US patent proceedings
As disclosed in February 2020, in response to Paragraph IV notices from multiple ANDA filers, AstraZeneca filed patent-infringement lawsuits in the US District Court for the District of Delaware. In its complaint, AstraZeneca alleged that a generic version of Tagrisso, if approved and marketed, would infringe a US Orange Book-listed Tagrisso patent. No trial date has been set.
 
Symbicort
US patent proceedings
As previously disclosed, AstraZeneca has ANDA litigation against Mylan Pharmaceuticals Inc. (Mylan) and 3M Company (3M) in the US District Court for the Northern District of West Virginia. In the action, AstraZeneca alleges that the defendants’ generic versions of Symbicort, if approved and marketed, would infringe various AstraZeneca patents. Mylan and 3M allege that their proposed generic medicines do not infringe the asserted patents and/or that the asserted patents are invalid and/or unenforceable. The trial of the Mylan and 3M matter is scheduled for October 2020.
 
Movantik
US patent proceedings
In March 2020, Aether Therapeutics, Inc. filed a patent infringement lawsuit in the US District Court for the District of Delaware against AstraZeneca, Nektar Therapeutics and Daiichi Sankyo relating to Movantik.
 
Commercial litigation
 
Amplimmune
As disclosed in the US in June 2017, AstraZeneca was served with a lawsuit filed by the stockholders' agents for Amplimmune, Inc. (Amplimmune) in Delaware State Court that alleged, among other things, breaches of contractual obligations relating to a 2013 merger agreement between AstraZeneca and Amplimmune. Trial of the matter was held in February 2020 and post-trial oral argument is scheduled for June 2020.
 
Government investigations/proceedings
 
Crestor
Qui tam litigation
As previously disclosed, in the US, in January and February 2014, AstraZeneca was served with lawsuits filed in the US District Court for the District of Delaware under the qui tam provisions of the federal False Claims Act and related state statutes, alleging that AstraZeneca directed certain employees to promote Crestor off-label and provided unlawful remuneration to physicians in connection with the promotion of Crestor. The Department of Justice and all US states declined to intervene in the lawsuits. In March 2019, AstraZeneca filed a motion to dismiss the complaint. In February 2020, the District Court partially granted AstraZeneca’s motion to dismiss.
 
Synagis
Litigation in New York
As disclosed in the US in June 2011, MedImmune received a demand from the US Attorney’s Office for the Southern District of New York requesting certain documents related to the sales and marketing activities of Synagis. In July 2011, MedImmune received a similar court order to produce documents from the Office of the Attorney General for the State of New York Medicaid and Fraud Control Unit pursuant to what the government attorneys advised was a joint investigation. MedImmune has co-operated with these inquiries. In March 2017, MedImmune was served with a lawsuit filed in US District Court for the Southern District of New York by the Attorney General for the State of New York, alleging that MedImmune inappropriately provided assistance to a single specialty-care pharmacy. In September 2018, the US District Court in New York denied MedImmune’s motion to dismiss the lawsuit brought by the Attorney General for the State of New York.
 
In June 2017, MedImmune was served with a lawsuit in US District Court for the Southern District of New York by a relator under the qui tam (whistle-blower) provisions of the federal and certain state False Claims Acts. The lawsuit was originally filed under seal in April 2009 and alleged that MedImmune made false claims about Synagis. In November 2017, MedImmune was served with an amended complaint in which relator set forth additional false claims’ allegations relating to Synagis. In September 2018, the US District Court in New York dismissed the relator’s lawsuit. In January 2019, relator appealed the decision of the US District Court in New York. In March 2020, the United States Court of Appeals for the Second Circuit affirmed the US District Court’s decision dismissing the relator’s lawsuit.
 
Vermont US Attorney investigation
In April 2020, AstraZeneca received a Civil Investigative Demand from the US Attorney’s Office in Vermont and the Department of Justice, Civil Division, seeking documents and information relating to AstraZeneca’s relationships with electronic health-record vendors. AstraZeneca intends to co-operate with this enquiry.
 
Taxation
As previously disclosed in the Annual Report and Form 20-F Information 2019, AstraZeneca faces a number of audits and reviews in jurisdictions around the world and, in some cases, is in dispute with the tax authorities. The issues under discussion are often complex and can require many years to resolve. Accruals for tax contingencies require management to make key judgements with respect to the ultimate outcome of current and potential future tax audits, and actual results could vary from these estimates. The total net accrual to cover the worldwide tax exposure for transfer pricing and other international tax contingencies of $139m (December 2019: $140m) reflected the progress in those tax audits and reviews during the half and for those audits where AstraZeneca and tax authorities are in dispute, AstraZeneca estimates the potential for reasonably possible additional liabilities above and beyond the amount provided to be up to $226m, including associated interest (December 2019: $76m). However, the Company believes that it is unlikely that these additional liabilities will arise. It is possible that some of these contingencies may reduce in the future to the extent that any tax authority challenge is concluded, or matters lapse following expiry of the relevant statutes of limitation resulting in a reduction in the tax charge in future periods.
 
There was no material change in the period to the other tax contingencies.
 
6)
Subsequent Events
In July 2020, the Company announced that it had entered into a new global development and commercialisation agreement with Daiichi Sankyo for DS-1062, its proprietary TROP2-directed antibody drug conjugate and potential new medicine for the treatment of multiple tumour types. AstraZeneca will pay Daiichi Sankyo an upfront payment of $1bn in staged payments, additional conditional amounts of up to $1bn for the successful achievement of regulatory approvals and up to $4bn for sales-related milestones. The transaction will be accounted for as an intangible-asset acquisition, recognised initially at the present value of non-contingent consideration, with any potential future milestone payments capitalised into the intangible asset as they are recognised.
 
The companies will jointly develop and commercialise DS-1062 jointly worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. AstraZeneca and Daiichi Sankyo will share equally development and commercialisation expenses as well as profits relating to DS-1062 worldwide, except for Japan where Daiichi Sankyo will be responsible for such costs and will pay AstraZeneca mid single-digit royalties. Daiichi Sankyo will record sales in the US, certain countries in Europe and certain other countries where Daiichi Sankyo has affiliates. Profits shared with AstraZeneca from those countries will be recorded as Collaboration Revenue by AstraZeneca. AstraZeneca will record Product Sales in other countries worldwide, for which profits shared with Daiichi Sankyo will be recorded within Cost of Sales. Daiichi Sankyo will manufacture and supply DS-1062.
 
 
7)
Table 41: Product Sales year-on-year analysis - H1 202074
 
 
 
World
Emerging Markets
US
Europe
Established RoW
$m
% change
$m
% change
$m
% change
$m
% change
$m
% change
Actual
CER
Actual
CER
Actual
Actual
CER
Actual
CER
Oncology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tagrisso
2,016
43
45
595
81
89
725
30
325
53
58
371
18
18
Imfinzi
954
51
52
63
n/m
n/m
574
21
167
n/m
n/m
150
70
71
Lynparza
816
57
60
120
n/m
n/m
406
55
198
51
56
92
35
34
Calquence
195
n/m
n/m
2
n/m
n/m
193
n/m
-
-
-
-
-
-
Koselugo
7
n/m
n/m
-
-
-
7
n/m
-
-
-
-
-
-
Zoladex*
442
13
18
288
22
29
5
40
68
5
8
81
(7)
(6)
Faslodex*
312
(40)
(38)
100
4
10
34
(87)
116
6
9
62
(4)
(4)
Iressa*
147
(42)
(40)
120
(27)
(24)
7
(3)
9
(81)
(81)
11
(67)
(66)
Arimidex*
107
(3)
-
90
26
30
-
-
1
(90)
(90)
16
(32)
(32)
Casodex*
89
(15)
(13)
69
8
11
-
-
1
(84)
(84)
19
(43)
(42)
Others
26
(50)
(47)
14
(23)
(14)
-
-
3
(15)
(16)
9
(64)
(69)
Total Oncology
5,111
26
28
1,461
39
46
1,951
20
888
37
41
811
10
9
BioPharmaceuticals: CVRM
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Farxiga
848
17
21
306
49
59
237
(12)
223
25
29
82
14
15
Brilinta
845
15
17
291
34
40
351
9
173
2
5
30
7
10
Onglyza
256
(5)
(3)
100
15
21
105
(12)
29
(21)
(18)
22
(15)
(13)
Bydureon
216
(24)
(23)
2
(74)
(72)
185
(21)
24
(29)
(26)
5
(37)
(34)
Byetta
35
(36)
(35)
5
13
21
19
(47)
7
(29)
(26)
4
(21)
(20)
Other diabetes
23
3
6
3
n/m
n/m
13
(21)
6
44
50
1
(60)
(25)
Lokelma
28
n/m
n/m
1
n/m
n/m
22
n/m
2
n/m
n/m
3
n/m
n/m
Crestor*
582
(10)
(8)
369
(9)
(6)
45
(17)
64
(15)
(13)
104
(5)
(5)
Seloken/Toprol-XL*
395
-
6
376
8
14
6
(78)
8
(39)
(39)
5
-
5
Atacand*
126
19
25
94
23
31
5
(15)
15
(2)
(2)
12
37
43
Others
106
(20)
(18)
65
(30)
(28)
-
-
35
15
18
6
(36)
(39)
BioPharmaceuticals: total CVRM
3,460
3
6
1,612
11
17
988
(9)
586
3
6
274
-
2
BioPharmaceuticals: Respiratory & Immunology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symbicort
1,442
23
26
290
10
16
558
46
356
1
4
238
39
42
Pulmicort
477
(33)
(32)
371
(36)
(34)
36
(36)
40
(8)
(4)
30
(26)
(25)
Fasenra
426
44
45
7
n/m
n/m
272
31
88
96
n/m
59
41
41
Daliresp/Daxas
106
1
2
2
(13)
(7)
90
1
13
7
11
1
(3)
(36)
Bevespi
22
10
10
-
-
-
21
5
1
n/m
n/m
-
-
-
Breztri
11
n/m
n/m
9
n/m
n/m
-
-
-
-
-
2
n/m
n/m
Others
184
(20)
(18)
80
(29)
(27)
7
n/m
89
(16)
(14)
8
(14)
4
BioPharmaceuticals: total Respiratory & Immunology
2,668
5
7
759
(21)
(18)
984
30
587
5
8
338
29
31
Other medicines
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nexium
714
(5)
(3)
371
-
5
80
(32)
36
14
18
227
(4)
(4)
Synagis
176
18
18
5
n/m
n/m
21
(40)
150
32
32
-
-
-
Losec/Prilosec
99
(32)
(30)
81
(15)
(12)
3
(44)
10
(68)
(68)
5
(62)
(62)
Seroquel XR/IR
63
(9)
(8)
27
11
15
14
n/m
15
(69)
(69)
7
(36)
(37)
Others
68
(32)
(31)
3
(64)
(73)
33
(44)
28
5
5
4
(34)
(22)
Total other medicines
1,120
(8)
(6)
487
(2)
1
151
(26)
239
(4)
(4)
243
(9)
(9)
Total Product Sales
12,359
11
13
4,319
9
14
4,074
11
2,300
13
17
1,666
8
9
 
8) 
Table 42: Product Sales year-on-year analysis - Q2 2020 (Unreviewed)75
 
 
World
Emerging Markets
US
Europe
Established RoW
$m
% change
$m
% change
$m
% change
$m
% change
$m
% change
Actual
CER
Actual
CER
Actual
Actual
CER
Actual
CER
Oncology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tagrisso
 1,034
 32
 35
 315
 65
 74
 354
 18
 163
 46
 51
 202
 12
 12
Imfinzi
 492
 46
 48
 30
 n/m
 n/m
 287
 19
 93
 n/m
 n/m
 82
 55
 56
Lynparza
 419
 48
 52
 64
 95
n/m
 209
 47
 96
 45
 50
 50
 20
 21
Calquence
 107
 n/m
 n/m
 1
n/m
n/m
 107
 n/m
 -
 -
 -
 (1)
n/m
n/m
Koselugo
 7
n/m
n/m
 -
 -
 -
 7
n/m
 -
 -
 -
 -
 -
 -
Zoladex*
 217
 10
 17
 139
 15
 24
 3
 55
 33
 8
 14
 42
 (4)
 (2)
Faslodex*
 146
 (45)
 (43)
 52
 2
 10
 11
 (91)
 52
 (7)
 (3)
 31
 (13)
 (13)
Iressa*
 70
 (41)
 (38)
 58
 (26)
 (23)
 4
 (5)
 3
 (85)
 (85)
 5
 (65)
 (62)
Arimidex*
 58
 (4)
 -
 48
 35
 41
 -
 -
 1
 (93)
 (93)
 9
 (42)
 (43)
Casodex*
 47
 (17)
 (15)
 37
 8
 11
 -
 -
 -
n/m
n/m
 10
 (47)
 (46)
Others
 12
 (59)
 (55)
 6
 (35)
 (18)
 (1)
n/m
 1
 (32)
 (35)
 6
 (67)
 (74)
Total Oncology
 2,609
 20
 24
 750
 34
 43
 981
 15
 442
 32
 37
 436
 3
 4
BioPharmaceuticals: CVRM
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Farxiga
 443
 17
 23
 165
 49
 62
 124
 (11)
 107
 20
 25
 47
 24
 26
Brilinta
 437
 12
 16
 156
 30
 39
 187
 11
 80
 (9)
 (5)
 14
 6
 10
Bydureon
 116
 (18)
 (17)
 1
 (87)
 (86)
 101
 (14)
 12
 (22)
 (19)
 2
 (23)
 (18)
Onglyza
 115
 (1)
 3
 52
 19
 27
 38
 (9)
 14
 (22)
 (19)
 11
 (20)
 (17)
Byetta
 15
 (42)
 (41)
 2
 (37)
 (30)
 7
 (53)
 4
 (16)
 (13)
 2
 (26)
 (26)
Other diabetes
 10
 (9)
 (5)
 1
n/m
n/m
 6
 (31)
 3
 37
 44
 -
n/m
n/m
Lokelma
 17
 n/m
 n/m
 1
n/m
n/m
 12
 n/m
 1
n/m
n/m
 3
n/m
n/m
Crestor*
 281
 (10)
 (6)
 177
 (3)
 2
 17
 (40)
 30
 (18)
 (16)
 57
 (11)
 (10)
Seloken/Toprol-XL*
 218
 29
 38
 210
 35
 45
 2
 (53)
 4
 (48)
 (48)
 2
 2
 9
Atacand*
 59
 6
 14
 45
 21
 33
 2
 (39)
 6
 (43)
 (43)
 6
 43
 52
Others
 48
 (23)
 (20)
 29
 (31)
 (28)
 -
 -
 16
 25
 29
 3
 (65)
 (69)
BioPharmaceuticals: total CVRM
 1,759
 6
 10
 839
 20
 28
 496
 (6)
 277
 (3)
 1
 147
 (1)
 1
BioPharmaceuticals: Respiratory & Immunology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symbicort
 653
 12
 15
 135
 3
 12
 248
 20
 161
 (6)
 (3)
 109
 42
 47
Pulmicort
 97
 (71)
 (69)
 58
 (78)
 (76)
 13
 (60)
 15
 (21)
 (18)
 11
 (43)
 (42)
Fasenra
 227
 36
 37
 1
 (30)
 (5)
 152
 33
 42
 57
 63
 32
 32
 33
Daliresp/Daxas
 53
 (7)
 (7)
 1
 (17)
 (9)
 45
 (7)
 6
 (3)
 1
 1
 (37)
 (70)
Bevespi
 10
 (1)
 (3)
 -
 -
 -
 9
 (6)
 1
n/m
n/m
 -
 -
 -
Breztri
 7
n/m
n/m
 5
n/m
n/m
 -
 -
 -
 -
 -
 2
n/m
n/m
Others
 70
 (30)
 (28)
 21
 (52)
 (52)
 5
n/m
 42
 (18)
 (15)
 2
 (60)
 (36)
BioPharmaceuticals: total Respiratory & Immunology
 1,117
 (11)
 (8)
 221
 (50)
 (46)
 472
 15
 267
 (3)
 1
 157
 23
 26
Other medicines
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nexium
 377
 (4)
 (1)
 184
 3
 9
 40
 (24)
 15
 (7)
 (4)
 138
 (5)
 (5)
Synagis
 90
 (5)
 (5)
 -
 -
 -
 14
 41
 76
 (11)
 (11)
 -
 -
 -
Losec/Prilosec
 45
 (34)
 (31)
 37
 (16)
 (12)
 1
 (90)
 5
 (60)
 (60)
 2
 (75)
 (74)
Seroquel XR/IR
 27
 (16)
 (14)
 15
 49
 57
 1
n/m
 7
 (71)
 (71)
 4
 (23)
 (25)
Others
 24
 (53)
 (52)
 2
 (88)
 (93)
 8
 (74)
 13
 3
 1
 1
n/m
n/m
Total other medicines
 563
 (12)
 (10)
 238
 (5)
 -
 64
 (29)
 116
 (23)
 (23)
 145
 (3)
 (3)
Total Product Sales
 6,048
 6
 9
 2,048
 5
 12
 2,013
 7
 1,102
 5
 9
 885
 4
 5
 
 
9) 
Table 43: Product Sales quarterly sequential analysis - Q2 2020 (Unreviewed)76
 
 
 
Q1 2020
Q2 2020
$m
% change
$m
% change
Actual
CER
Actual
CER
Oncology
 
 
 
 
 
 
Tagrisso
982
11
11
1,034
5
7
Imfinzi
462
9
9
492
6
8
Lynparza
397
13
13
419
5
7
Calquence
88
58
58
107
21
23
Koselugo
 -
- 
- 
7
n/m
n/m 
Zoladex*
225
15
15
217
(3)
-
Faslodex*
166
-
-
146
(12)
(9)
Iressa*
77
(3)
(4)
70
(9)
(7)
Arimidex*
50
(1)
(2)
58
17
16
Casodex*
42
(2)
(3)
47
14
12
Others
13
(52)
(52)
12
(11)
(1)
Total Oncology
2,502
10
10
2,609
4
6
BioPharmaceuticals: CVRM
 
 
 
 
 
 
Farxiga
405
(3)
(3)
443
9
13
Brilinta
408
(5)
(5)
437
7
9
Onglyza
141
8
8
115
(19)
(17)
Bydureon
100
(28)
(28)
116
16
17
Byetta
20
(24)
(24)
15
(28)
(28)
Other diabetes
13
(22)
(22)
10
(21)
(19)
Lokelma
11
42
42
17
56
58
Crestor*
301
2
1
281
(7)
(4)
Seloken/Toprol-XL*
177
(6)
(6)
218
23
27
Atacand*
66
11
12
59
(11)
(5)
Others
59
(21)
(22)
48
(18)
(16)
BioPharmaceuticals: total CVRM
1,701
(5)
(5)
1,759
3
6
BioPharmaceuticals: Respiratory & Immunology
 
 
 
 
 
 
Symbicort
790
11
11
653
(17)
(15)
Pulmicort
380
(8)
(9)
97
(74)
(73)
Fasenra
199
(3)
(3)
227
14
15
Daliresp/Daxas
53
(8)
(8)
53
(1)
(3)
Bevespi
12
9
9
10
(19)
(21)
Breztri
4
n/m
n/m
7
58
64
Others
113
(16)
(17)
70
(38)
(36)
BioPharmaceuticals: total Respiratory & Immunology
1,551
1
1
1,117
(28)
(26)
Other medicines
 
 
 
 
 
 
Nexium
338
(4)
(4)
377
12
14
Synagis
85
35
35
90
6
7
Losec/Prilosec
54
18
17
45
(15)
(15)
Seroquel XR/IR
36
(12)
(12)
27
(26)
(23)
Others
44
(71)
(70)
24
(46)
(42)
Total other medicines
557
(15)
(15)
563
1
4
Total Product Sales
6,311
1
1
6,048
(4)
(2)
 
 
10) 
T able 44: Product Sales quarterly sequential analysis - FY 2019 (Unreviewed)
 
 
 
Q1 2019
Q2 2019
Q3 2019
Q4 2019
$m
% change
$m
% change
$m
% change
$m
% change
Actual
CER
Actual
CER
Actual
CER
Actual
CER
Oncology
 
 
 
 
 
 
 
 
 
 
 
 
Tagrisso
630
6
6
784
24
25
891
14
13
884
(1)
-
Imfinzi
295
13
13
338
15
15
412
22
22
424
3
4
Lynparza
237
13
13
283
19
20
327
16
15
351
7
8
Calquence
29
21
23
35
21
19
44
27
27
56
25
25
Faslodex*
254
(6)
(6)
267
5
6
205
(23)
(23)
166
(20)
(19)
Zoladex*
194
7
6
197
2
1
226
15
16
196
(14)
(12)
Iressa*
134
20
18
118
(12)
(11)
91
(23)
(22)
80
(13)
(12)
Arimidex*
51
11
10
60
18
17
63
5
5
51
(20)
(18)
Casodex*
48
4
3
57
19
18
52
(8)
(6)
43
(18)
(17)
Others
20
(13)
(14)
28
40
29
20
(27)
(22)
26
30
26
Total Oncology
1,892
7
6
2,167
15
15
2,334
8
8
2,274
(3)
(2)
BioPharmaceuticals: CVRM
 
 
 
 
 
 
 
 
 
 
 
 
Farxiga
349
(12)
(12)
377
8
9
398
5
5
419
5
6
Brilinta
348
(7)
(8)
389
12
12
416
7
8
428
3
3
Onglyza
153
3
3
116
(24)
(24)
127
9
11
131
3
4
Bydureon
142
3
3
141
(1)
-
127
(10)
(10)
139
9
10
Byetta
30
(6)
(5)
25
(17)
(16)
28
10
13
27
(2)
(4)
Other diabetes
11
(8)
(17)
11
-
8
14
26
22
16
17
17
Lokelma
-
n/m
n/m
2
n/m
n/m
4
n/m
n/m
8
87
74
Crestor*
335
(5)
(6)
310
(7)
(7)
337
9
9
296
(12)
(11)
Seloken/Toprol-XL*
225
41
38
168
(25)
(25)
177
6
8
190
7
8
Atacand*
50
(14)
(15)
56
12
14
55
(1)
(1)
60
8
9
Others
71
(3)
(5)
63
(11)
(8)
65
4
2
72
13
16
BioPharmaceuticals: total CVRM
1,714
(2)
(3)
1,658
(3)
(3)
1,749
5
6
1,785
2
3
BioPharmaceuticals: Respiratory & Immunology
 
 
 
 
 
 
 
 
 
 
 
 
Symbicort
585
(8)
(8)
585
-
1
613
5
4
712
16
17
Pulmicort
383
(2)
(2)
333
(13)
(13)
337
1
3
413
22
23
Fasenra
129
3
4
167
29
30
202
21
21
206
2
2
Daliresp/Daxas
48
(11)
(12)
56
17
18
53
(6)
(7)
58
10
10
Bevespi
10
-
(5)
10
-
2
10
4
8
12
8
5
Breztri
-
-
-
-
-
-
1
-
-
1
(74)
(73)
Others
128
(14)
(12)
101
(21)
(23)
102
1
(1)
135
33
38
BioPharmaceuticals: total Respiratory & Immunology
1,283
(6)
(6)
1,252
(2)
(2)
1,319
5
6
1,537
17
17
Other medicines
 
 
 
 
 
 
 
 
 
 
 
 
Nexium
363
(7)
(8)
393
8
8
374
(5)
(4)
353
(6)
(6)
Synagis
53
(79)
(79)
96
81
81
146
52
53
63
(57)
(57)
Losec/Prilosec
76
27
26
68
(11)
(10)
73
8
9
46
(38)
(38)
Seroquel XR/IR
37
(34)
(33)
32
(14)
(10)
82
n/m
n/m
40
(50)
(49)
Others
47
(65)
(64)
52
11
11
56
8
-
151
n/m
n/m
Total other medicines
576
(35)
(36)
641
11
12
731
14
14
653
(11)
(10)
Total Product Sales
5,465
(5)
(6)
5,718
5
5
6,132
7
8
6,250
2
3
 

 
 
Table 45: Historic Collaboration Revenue (Unreviewed)
 
 
 
H1 2020
H1 2019
FY 2019
FY 2018
$m
$m
$m
$m
Initial Collaboration Revenue
Crestor (Spain)
-
-
-
61
Ongoing Collaboration Revenue
Lynparza: regulatory milestones
135
60
60
140
Lynparza: sales milestones
-
-
450
250
Lynparza/selumetinib: option payments
-
-
100
400
Crestor (Spain)
-
-
39
-
Enhertu: profit share
36
-
-
-
Roxadustat: profit share
11
-
-
-
Royalty income
34
32
62
49
 
Other Collaboration Revenue
54
39
108
141
Total
270
131
819
1,041
 
Table 46: Other Operating Income and Expense (Unreviewed)
 
The table below provides an analysis of Reported Other Operating Income and Expense.
 
 
H1 2020
H1 2019
FY 2019
FY 2018
$m
$m
$m
$m
Hypertension medicines (ex-US, India and Japan)
350
-
-
-
Inderal, Tenormin, Seloken and Omepral (Japan)
51
-
-
-
Synagis (US)
-
515
515
-
Losec (ex-China, Japan, US and Mexico)
-
-
243
-
Seroquel and Seroquel XR (US, Canada, Europe and Russia)
-
-
213
-
Arimidex and Casodex (various countries)
-
-
181
-
Nexium (Europe) and Vimovo (ex-US)
-
-
-
728
Seroquel
-
-
-
527
Legal settlement
-
-
-
346
Atacand
-
-
-
210
Anaesthetics
-
-
-
172
Alvesco, Omnaris and Zetonna
-
-
-
139
Other
200
191
389
405
 
 
 
 
 
Total
601
706
1,541
2,527
 
 
 
Shareholder information
 
Announcement of year to date and third quarter results                                                             5 November 2020
Announcement of full year and fourth quarter results                                                               11 February 2021
 
Future dividends will normally be paid as follows:
First interim:
announced with half-year and second-quarter results and paid in September
Second interim:
announced with full-year and fourth-quarter results and paid in March
 
The record date for the first interim dividend for 2020, payable on 14 September 2020, will be 14 August 2020. The ex-dividend date will be 13 August 2020.
 
Trademarks of the AstraZeneca group of companies appear throughout this document in italics. Medical publications also appear throughout the document in italics. AstraZeneca, the AstraZeneca logotype and the AstraZeneca symbol are all trademarks of the AstraZeneca group of companies. Trademarks of companies other than AstraZeneca that appear in this document include Alvesco, Omnaris and Zetonna, trademarks of Covis Pharma; Atacand, owned by AstraZeneca or Cheplapharm (depending on geography); Avastin, a trademark of Genentech, Inc.; Duaklir, Eklira and Tudorza, trademarks of Almirall, S.A.; Enhertu, a trademark of Daiichi Sankyo; Losec, owned by AstraZeneca, Cheplapharm or Taiyo Pharma Co., Ltd (depending on geography); Seloken, owned by AstraZeneca or Taiyo Pharma Co., Ltd (depending on geography); Synagis, owned by Arexis AB or AbbVie Inc. (depending on geography); Vimovo, owned by AstraZeneca or Grünenthal GmbH (depending on geography).
 
Information on or accessible through AstraZeneca’s websites, including astrazeneca.com, does not form part of and is not incorporated into this announcement.
 
Addresses for correspondence
 
 
 
 
 
Registered office
Registrar and transfer office
Swedish Central Securities Depository
US depositary
Deutsche Bank Trust Company Americas
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
 
United Kingdom
United Kingdom
Sweden
United States
 
 
 
 
+44 (0) 20 3749 5000
0800 389 1580
+46 (0) 8 402 9000
+1 (888) 697 8018
 
+44 (0) 121 415 7033
 
+1 (718) 921 8137
 
 
 
 [email protected]
 
Cautionary statements regarding forward-looking statements
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement:
 
This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things:
 
-
the risk of failure or delay in delivery of pipeline or launch of new medicines
-
the risk of failure to meet regulatory or ethical requirements for medicine development or approval
-
the risk of failure to obtain, defend and enforce effective intellectual property (IP) protection and IP challenges by third parties
-
the impact of competitive pressures including expiry or loss of IP rights, and generic competition
-
the impact of price controls and reductions
-
the impact of economic, regulatory and political pressures
-
the impact of uncertainty and volatility in relation to the UK’s exit from the EU
-
the risk of failures or delays in the quality or execution of the Group’s commercial strategies
-
the risk of failure to maintain supply of compliant, quality medicines
-
the risk of illegal trade in the Group’s medicines
-
the impact of reliance on third-party goods and services
-
the risk of failure in information technology, data protection or cybercrime
-
the risk of failure of critical processes
-
any expected gains from productivity initiatives are uncertain
-
the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce
-
the risk of failure to adhere to applicable laws, rules and regulations
-
the risk of the safety and efficacy of marketed medicines being questioned
-
the risk of adverse outcome of litigation and/or governmental investigations
-
the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation
-
the risk of failure to achieve strategic plans or meet targets or expectations
-
the risk of failure in financial control or the occurrence of fraud
-
the risk of unexpected deterioration in the Group’s financial position
-
and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group’s ability to continue to mitigate these risks, and on the Group’s operations, financial results or financial condition
Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.
 
 
 
11 Homologous recombination deficiency positive.
12 Breast cancer susceptibility gene 1/2 mutation.
13 Homologous recombination repair mutation.
14 Heart failure.
15 CV outcomes trial.
16 Coronary artery disease.
17 Type-2 diabetes.
18 Chronic obstructive pulmonary disease.
19 Human epidermal growth factor receptor 2 positive.
20 Extensive stage.
21 Small cell lung cancer.
22 Non-small cell lung cancer.
23 HER2 mutation.
24 Chronic lymphocytic leukaemia.
25 Neurofibromatosis type 1, a genetic condition causing tumours to grow along nerves in the skin, brain and other parts of the body.
26 Chronic kidney disease
27 Epidermal growth factor receptor-mutated.
28 The tumour cannot be removed completely through surgery.
29 Tremelimumab.
30 Painless, benign soft growths inside the nose.
31 Systemic lupus erythematosus, a chronic autoimmune disease that causes inflammation in connective tissues throughout the body.
32 HER2 immunohistochemistry (IHC) 1+ or 2+ with fluorescence in situ hybridisation (ISH) test-result negative.
33 HF with preserved ejection fraction.
34 Over the counter.
35 Substitution of threonine (T) with methionine (M) at position 790 of exon 20 mutation.
36 Here, excludes any Collaboration Revenue associated with the aforementioned collaboration with MSD.
37 Core financial measures are adjusted to exclude certain items. For more information on the Reported to Core financial adjustments, please refer to the introduction to the operating and financial review.
38 Core financial measures are adjusted to exclude certain items. For more information on the Reported to Core financial adjustments, please refer to the introduction to the operating and financial review.
39 Where AstraZeneca does not retain a significant ongoing interest in medicines or potential new medicines, income from divestments is reported within Other Operating Income and Expense in the Company’s financial statements.
40 As per the FY 2019 results announcement.
41 Based on average daily spot rates in FY 2019.
42 Based on average daily spot rates from 1 January 2020 to 30 June 2020.
43 Other currencies include AUD, BRL, CAD, KRW and RUB.
44 These priorities were determined through a materiality assessment conducted in 2018 with a broad range of external and internal stakeholders, respectively. Combined, they ensure the maximum possible benefit to patients, the Company, broader society and the planet. AstraZeneca’s sustainability priorities align with the United Nations Sustainable Development Goals (SDG), and, in particular, SDG three for ‘Good Health’.
45 Phase II/IIb trial with potential for registration.
46 First patient commenced dosing.
47 Last patient commenced dosing.
48 The European Medicines Agency committee responsible for human medicines.
49 Conducted by the Canadian Cancer Trials Group.
50 Progression-free survival.
51 Bacillus Calmette-Guerin.
52 Hepatocellular carcinoma.
53 Transarterial chemoembolisation.
54 Head and neck squamous cell carcinoma.
55 The US Orphan Drug Act grants special status to a medicine or potential medicine to treat a rare disease or condition upon request of a sponsor. Designation qualifies the sponsor of the medicine for various development incentives.
56 Conducted by the ARCAGY/Groupe d’Investigateurs national des Etudes des Cancers Ovariens et du sein.
57 IHC 3+ and IHC 2+/ISH.
58 Quaque die, or once a day.
59 Bis in die, or twice a day.
60 A specific situation in which a medicine should not be used as a treatment as it may be harmful to the patient.
61 Once every 8 weeks
62 Subcutaneous injection
63 A rare autoimmune condition that causes inflammation of small and medium-sized blood vessels.
64 Once every 4 weeks
65 Birmingham Vasculitis Activity Score.
66 Hypereosinophilic syndrome, a group of rare blood disorders.
67 White blood cells gather in the lining of the oesophagus.
68 Patient-reported outcomes.
69 The dates in the table referring to anticipated data for the accelerated development programme for AZD1222 refer to initial data, the timing of which are uncertain and subject to change resulting from factors such as changes in the level of community transmission. The timelines provided represent the best, current estimate of when initial efficacy data may be available.
70 Conducted by University of Oxford.
71 Conducted by University of Witwatersrand, South Africa.
72 Human immunodeficiency virus-positive.
73 Conducted by University of Oxford.
74 Sponsored by UK Government’s Therapeutics Taskforce.
75 Conducted by Cambridge University Hospitals NHS Trust.
76 Sponsored by the UK Government’s Therapeutics Taskforce.
77 Sponsored by Fundació Clinic per a la Recerca Biomèdica.
78 Conducted by University of Oxford.
79 Conducted by Direction de la Recherche Clinique et de l’Innovation L’Assistance Publique - Hôpitaux de Paris (DRCI AP-HP).
80 The Q2 2020 and Q2 2019 information in respect of the three months ended 30 June 2020 and 30 June 2019 respectively included in the Interim Financial Statements has not been reviewed by PricewaterhouseCoopers LLP.
81 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. *Denotes a legacy medicine.
82 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. The Q2 2020 information in respect of the three months ended 30 June 2020 included in the Interim Financial Statements has not been reviewed by PricewaterhouseCoopers LLP. *Denotes a legacy medicine.
83 The table provides an analysis of sequential quarterly Product Sales, with actual and CER growth rates reflecting quarter-on-quarter growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Sequential quarterly Product Sales information included in the Interim Financial Statements has not been reviewed by PricewaterhouseCoopers LLP. *Denotes a legacy medicine.
84 The table below provides an analysis of sequential quarterly Product Sales, with actual and CER growth rates reflecting quarter-on-quarter growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. The sequential quarterly Product Sales information included in the Interim Financial Statements has not been reviewed by PricewaterhouseCoopers LLP. *Denotes a legacy medicine.
85 Historic Collaboration Revenue information included in the table above has not been reviewed by PricewaterhouseCoopers LLP.
86 The Other Operating Income and Expense information included in the table above has not been reviewed by PricewaterhouseCoopers LLP.
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
 
Date: 30 July 2020
 
 
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary